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CHAPTER 1: INTRODUCTION TO TUBERCULOSIS  
1.1 Tuberculosis: past and present 
Tuberculosis (TB) is one of the ancient and deadliest human communicable disease of world, still 
representing a huge health, social and economic problem (1). TB is a global pandemic for many reason: the 
lack of an effective vaccine, the long and expensive therapy and the higher incidence especially in low and 
middle income countries.  Although TB is one of most studied infectious disease, since the study of R. Koch 
more than 100 years ago,  we have not still completely understood the mechanisms of TB pathogenesis and 
which factors can protect from developing the disease. The TB disease has been endemic in Europe 
throughout the Middle Ages and during the 18th and 19th centuries a list of cofactors such as lack of 
treatment, overcrowding and poor hygiene increased the spread of the infection and the mortality (2). The 
first attempts to treat the disease were based on recovery of patients in sanatoria and alleviation of 
symptoms by pneumothorax without knowing the real etiology of the disease (2). In the 1882 Robert Koch 
finally identified the Mycobacterium tuberculosis (Mtb) as the bacteria responsible of TB (3). In the 
following years the development of the vaccine based on the immunity against the Bacillus Calmette-
Guérin (BCG) (1921) (4), the use of antibiotics to fight the infection, streptomycin in 1943 and isoniazid and 
the rifamycins later (2), deeply improved the protection against the disease.  However, still today TB 
remains a major cause of morbidity and mortality. 
 
The specie of Mycobacterium tuberculosis complex (MTBC) are the etiologic agents of TB. MTBC includes: 
Mycobacterium tuberculosis, determining TB in humans; M. africanum, (human TB only in certain regions of 
Africa); M. bovis, M. caprae and M. pinnipedii, (TB in wild and domesticated mammals); M. microti, (TB only 
in voles). Mycobacterium tuberculosis emerged as a human pathogen in Africa 75-150 thousand years ago 
and spread by clonal expansion among human communities, following the migration flux, since then, giving 
rise to seven phylogeographic lineages with limited genetic variability, consisting of large sequence 
polymorphisms (LSPs) and single nucleotide polymorphisms (SNPs) (5-7). The ancient Mtb strains evolved 
to persist in low density populations, causing disease reactivation following long period of latent infection 
(8). The animal domestication permitted the transmission of tuberculosis from human to animal and M. 
bovis became the agent of TB in domestic and wild animals (7). Civilization and consequently higher density 
of human population have contributed to select modern Mtb strains with increased virulence and 
transmissibility (5,9). The present pandemics in sub-saharan Africa, South-East Asia and Eastern Europe are 
caused by the modern lineages 2, 3 and 4, whereas the ancient lineage 1 are responsible of the TB cases 
mainly in the Indo-Oceanic regions and the Philippines (10).  
In 2015, there were an estimated 10.4 million new (incident) TB cases worldwide, of which 5.9 million 
(56%) were among men, 3.5 million (34%) among women and 1.0 million (10%) among children. People 
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living with HIV accounted for 1.2 million (11%) of all new TB cases. Six countries accounted for 60% of the 
new cases: India, Indonesia, China, Nigeria, Pakistan and South Africa. Worldwide, the rate of decline in TB 
incidence remained at only 1.5% from 2014 to 2015. In 2015, there were an estimated 480 000 new cases 
of multidrug-resistant TB (MDR-TB) and an additional 100 000 people with rifampicin-resistant TB (RR-TB) 
who were also newly eligible for MDR-TB treatment. India, China and the Russian Federation accounted for 
45% of the combined total of 580 000 cases. There were an estimated 1.4 million TB deaths in 2015, and an 
additional 0.4 million deaths resulting from TB disease among people living with HIV. Although the number 
of TB deaths fell by 22% between 2000 and 2015, TB remained one of the top 10 causes of death 
worldwide in 2015 (11). Considering that with an early diagnosis and an appropriate therapy, TB disease 
can be treated, the number of deaths is unacceptably high. Moreover, it is estimated that a quarter of the 
global population is latently (asymptomatically) infected with Mtb (12), and approximately 3 to 10% of 
these infected individuals could develop active TB disease during their life (13-15). For all these reasons,  all 
efforts to fight TB must be intensified. 
 
 
1.2 Mycobcaterium tuberculosis  
Mtb is an obligate intracellular pathogen able to infect several animal species, although human population 
represents the main hosts. It has the following microbiological characteristics: aerobic, acid-fast, non-
motile, non-encapsulated and non-spore forming bacillus, it needs 15-20 h to complete a replication cycle. 
It grows most successfully in high oxygen environment , such as in the lung tissue. Mtb is neither gram 
positive nor gram negative, it is described as acid-fast because after the staining it resists to the acidified 
organic solvents used for the decolourisation process (3). 
Mycobacteria possess an external membrane consisting of an asymmetric lipid bilayer made of long fatty 
acids in the inner leaflet (mycolic acids) and of glycolipids and waxy components on the outer layer.  
The outer and inner membrane form a periplasmic space, with the presence of a thin layer of peptidoglycan 
in the innermost side covalently linked to arabinogalactan and lipoarabinomannan which in turn are bound 
to mycolic acids. The targeting of mycolic acids and arabinogalactan synthesis is at the base of two of the 
most successful anti-TB drugs isoniazid and ethambutol (16). 
The main virulence factors of Mb are the protein secretion systems (ESX1-5) (17). ESX1 is necessary to 
translocate the bacteria from the phagosome into the cytosol of  macrophages (18-20) and it secretes two 
small and highly immunogenic proteins, ESAT-6 and CFP-10, used in the interferon-gamma release assays 
(IGRAs) for the immunological diagnosis of Mtb infection (21). ESX3 is implicated in the acquisition of iron 
and zinc whereas ESX5, found only in MTBC, M. marinum and M. ulcerans,  interacts with host immune 
system (16). 
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The dormancy survival regulon (Dos), controls expression of more than 50 genes responsible for the Mtb  
response to hypoxic conditions and for the survival of the bacteria in the host (22,23). The Mtb resides in 
macrophages and ganuloma characterized by low oxygen and nutrient depletion, in response to this 
particular milieu the Mtb induce a dormant state of the bacilli,  inhibiting the replication, down-regulating  
metabolism and activating an anaerobic metabolism (24). 
 
1.3 Pathogenesis 
 
TB is a communicable disease, transmitted exclusively when few tubercle bacilli dispersed in the air from a 
patient with active pulmonary TB, reach the alveoli of the host. The risk of infection depends on the 
bacillary load present in the cough aerosol of the index case, the duration and intensity of exposure, Mtb 
strain-specific virulence factors and the immune status of the contact (25). TB is characterized 
pathologically by necrotizing granulomatous inflammation usually in the lung, although almost any extra-
pulmonary site can be involved. Upon inhalation, the droplet nuclei travel through the respiratory tract, 
escaping the mucosal barriers in the bronchi, and eventually end up in the terminal alveoli where 
macrophages, dendritic cells (DCs) and neutrophils engulf the bacteria (26-28). During the early stages of 
infection, if the bacilli evade the initial host innate immune mechanisms, it starts actively replicating in 
macrophages, diffuse to nearby cells including epithelial and endothelial cells, causing a high bacterial 
burden with few weeks of replication (29). Infected DCs and macrophages also travel to the local lymph 
node where T-cells are primed and clonally expand in response to Mtb antigens. These antigen specific T 
cells then migrate back to the site of infection in 2-6 weeks after initial infection (30). After the activation of 
adaptive immune response, the migration to the site of primary infection of neutrophils, lymphocytes and 
monocytes create a typical and organized  cellular infiltrate called granuloma (31,32). Fibrotic components 
around the granuloma leads to its calcification, therefore the bacilli remain isolated inside it and at the 
same time protected by the host immune response.  
Although tuberculosis predominantly affects the lung, it can cause disease in any organ and must be 
included within the differential diagnosis of a vast range of clinical presentations. Symptoms and signs 
include those associated with the specific disease site as well as non-specific constitutional symptoms such 
as fever, weight loss, and night sweats (3). However, in the early stages of disease, symptoms might be 
absent as shown by community-based active case finding studies in Asia in which about one in four culture-
confirmed cases of pulmonary tuberculosis were reported to be asymptomatic (3). 
In the majority (~95%) of infected individuals, pathogenesis is characterized by a period of asymptomatic 
subclinical infection, defined broadly as latent tuberculosis infection (LTBI), in this state the bacilli are 
effectively contained within the granuloma (33,34). In this primary lesion, Mtb persists in a dormant, non-
metabolically active state, for years, decades, or lifetime. LTBI, defined as a state of persistent immune 
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response to prior-acquired Mycobacterium tuberculosis antigens without evidence of clinically manifested 
active TB, affects about a quarter of the global population (12). Approximately 5-10% of people with LTBI 
will develop active TB disease in their lifetime, with the majority developing it within the first five years 
after initial infection (35). It could be detected either by the tuberculin skin test (TST) or by interferon (IFN)-
γ release assay (IGRA) without signs of clinically TB (14). Based on this definition, subjects with LTBI carry a 
risk to develop the active TB disease. However, the majority of LTBI individuals will not develop TB, 
probably because their immune system persistently inhibits the mycobacterial replication or because the 
bacilli has been totally eradicated. Until recently, LTBI was thought to represent a uniform state, however, 
it has become clear that LTBI has to be considered a broad spectrum of infection states that differ by the 
degree of the pathogen replication, host resistance and inflammation (36). In vivo studies on non-human 
primate have demonstrated that during latent infection, Mtb is metabolically active and replicates in host 
tissues even though the absence of any clinical signs of TB disease (37). To note that a single monkey with 
active TB shows different type of lesions: liquefied cavities with high bacterial load, necrotic or caseous 
hypoxic lesions with variable number of bacilli and sterilized lesions (36). Similarly, TB disease presentation 
is diverse and heterogeneous. This heterogeneity includes the type of pathology developed in the lungs 
(pulmonary TB) or outside the lungs (extrapulmonary TB), the spread of the lesions, the characteristics of 
immune activation and inflammation, Mtb replication and bacterial load (37), the capacity of the TB lesions 
to differently respond to chemotherapy (36). An increasing body of evidence supports the hypothesis that 
the genetic background of the host influences TB disease manifestations and the success of the bacterium 
in infecting large numbers of susceptible individuals (38). The active TB patients represent the primary 
source of disease transmission. The concept of TB spectrum emphasize the risk that a latent infection 
condition, controlled by the host immune response with no clinical signs or symptoms, can reactivate if the 
balance between host and Mtb is interrupted. In fact, the risk of Mtb reactivation is significantly increased 
in LTBI individuals with a concomitant immune suppression, due to HIV co-infection or therapy with tumour 
necrosis factor (TNF)-α inhibitors, or other immune regulators used for inflammatory diseases and 
transplantation or compromised immunity due to non communicable diseases, such as type 2 diabetes 
(30,39,40). Therefore, it is very important to develop effective diagnostic tools to detect latent infection in 
these high risk individuals and very sensitive assays to identify new TB cases. 
Animal models such as mice, guinea pigs, rabbits, macaques, and zebrafish have been used to study the 
pathogenesis and treatment of latent tuberculosis. Common limit to all models is the absence of 
pathological, clinical, and therapeutic consistency with human infection and disease. Therefore, different 
models could be used to study particular aspect similar to the human infection (35). 
In conclusion, Mtb infection can result in a spectrum of disease phenotypes characterized by different 
immunodiagnostic, clinical and radiological profiles. Host immunity certainly plays an important role in the 
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host-pathogen interaction to determine the outcome of infection but how the immune response controls 
the infection or contribute to the development of active TB remains poorly understood. 
 
 
1.4 Diagnosis of active tuberculosis 
Accurate and early diagnosis is essential to permit TB control. The detection of Mtb in sputum, correlates 
with the presence of necrotic infection lesion in proximity to the airways. Although the microscopy is 
largely available and highly specific, it shows low sensitivity, missing the diagnosis in over one third of 
patients (41,42). Mycobacterial culture is the gold standard for TB diagnosis, due to its superior sensitivity, 
although detection can take weeks resulting in significant delays in treatment initiation (16). 
Since many TB patients, such as HIV-coinfected individuals, diabetes patients, and children, do not have a 
Mtb-positive sputum, these test is useless in these particular populations (13,43,44). By definition, sputum 
diagnostics are not useful in extra-pulmonary disease. Non-pulmonary forms of TB may be more 
problematic to diagnose because of the difficulties in identifying the proper specimens (tissue or biological 
fluids as pleural-, cerebral-, synovial-fluids collected by invasive procedures) and the lower sensitivity of the 
microbiological assays, probably due to a lower bacterial concentration (14). In conclusions, definitive 
diagnosis of TB needs the detection of Mtb from the biological sample by at least one of the following 
techniques: microscopical analysis, culture isolation or molecular methods. The introduction of new, highly 
sensitive, fully automated molecular assays, is the major success of the TB diagnosis (14). In fact the Gene 
Xpert MTB/RIF assay, a cartridge based real-time PCR system that can detect Mtb DNA and genotypic 
rifampicin resistance in ~2 hours (45), reducing the time to diagnosis and treatment initiation. 
 
 
1.5 Immunological diagnosis of latent tuberculosis infection 
 
With a quarter of the world population infected with Mtb (12), it is important to identify latently infected 
individuals who may progress to active TB, such as those who are HIV infected. LTBI is defined by the 
presence of a specific immune response detected by an IFNγ release assay (IGRA) or the tuberculin skin test 
(TST) in the absence of signs or symptoms of TB and without lung lesions of active TB in xRay images (35). 
Diagnosis of LTBI is difficult because it is based on the presence of immunological memory to Mtb antigens 
rather than the direct assessment of mycobacterial load. 
IGRA, such as QuantiFERON®-TB Gold Plus (QFT-Plus) (Qiagen, Hilden, Germany) and T-SPOT.TB (Oxford 
Immunotec, Marlborough, MA, USA) measure in vitro IFNγ production by whole blood ELISA or an enzyme-
linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMC), respectively (14,46). 
Blood cells are stimulated with Mtb-specific antigens (47), which are deleted from the genome of  Bacille 
6 
 
Calmette and Guerin (BCG) vaccine (the attenuated strain of M.bovis), and are not present in most 
environmental mycobacteria (48,49). Since the vaccinal strain does not express ESX1 and ESAT-6 and CFP-
10, IGRAs can be used to detect Mtb infection even in vaccinated population (14). TST, in use for over 100 
years, is based on skin infiltration, through intradermal injection of purified protein derivative (PPD), which 
is a crude mixture of antigens many of which are shared by Mtb, M. bovis, BCG and several species of 
environmental mycobacteria. The TST elicits a delayed type hypersensitivity immune reaction at the site of 
injection visible between 48 and 72 hours after administration.  When placed correctly, the injection should 
produce a pale elevation of the skin (a wheal) 6 to 10 mm in diameter (50). However, the test suffers from 
poor specificity due to previous BCG vaccination and exposure to environmental mycobacteria (14). 
A particular benefit of in vitro testing is that there is a laboratory test with negative and positive controls, 
and that one visit suffices. In contrast to the TST, these in vitro tests may discriminate true negative 
responses from energy (14). 
However all these tests have limitations as they cannot distinguish between latent infection with viable 
microorganisms and healed/treated infections; they also poorly predict who will progress to active TB (14). 
 
1.6 Therapy 
To cure TB and reduce disease transmission, patients should be placed on effective treatment soon after 
diagnosis. TB disease can be treated by taking several drugs for 6 to 9 months (50). There are 10 drugs 
currently approved by the U.S. Food and Drug Administration (FDA) for treating TB. Of the approved drugs, 
the first-line anti-TB agents that form the core of treatment regimens are: isoniazid (INH), rifampin 
(RIF),ethambutol (EMB) and pyrazinamide (PZA). Drug-resistant TB can occur when the drugs used to treat 
TB are misused or mismanaged. Examples of misuse or mismanagement include the following situations: 
people do not complete a full course of TB treatment; health care providers prescribe the wrong treatment 
(the wrong dose or length of time), drugs for proper treatment are not available, drugs are of poor quality. 
Drug-resistant TB is more common in people who: do not take their TB drugs regularly; do not take all of 
their TB drugs; develop TB disease again, after being treated for TB disease in the past; come from areas of 
the world where drug-resistant TB is common; have spent time with someone known to have drug-
resistant TB disease (50). Multidrug-resistant TB (MDR TB) is caused by TB bacteria that is resistant to at 
least isoniazid and rifampin, the two most potent TB drugs. Extensively drug-resistant TB (XDR TB) is a rare 
type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of 
three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Because XDR TB is resistant 
to the most potent TB drugs, patients are left with treatment options that are much less effective (50). 
According WHO, LTBI (1) can be effectively treated in order to prevent progression to active TB, thus 
resulting in a substantial benefit for both the individual and the community. Currently, available treatments 
for subjects with LTBI have an efficacy ranging from 60% to 90%. Systematic testing and treatment of LTBI 
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in at-risk populations is a critical component of WHO’s eight-point framework adapted from the End TB 
Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. The risk of 
progression to active disease is considerably higher in infected individuals who belong to specific high risk 
populations. Major risk factors for TB activation include: 
 HIV infection 
 recent contact with an infectious patient 
 initiation of an anti-tumour necrosis factor (TNF) treatment 
 receiving dialysis 
 receiving an organ or hematologic transplantation 
 silicosis 
 being in prison 
 being an immigrant from high TB burden countries 
 being a homeless person 
 being an illicit drug user 
 
The following regimens are recommended by WHO for the treatment of LTBI: 
 6-month or 9-month isoniazid daily 
 3-month rifapentine plus isoniazid weekly 
 3- or 4-month isoniazid plus rifampicin daily 
 3– or 4-month rifampicin alone daily 
 
1.7 The immune response to Mycobacterium tuberculosis infection  
Inhalation of a small number of M. tuberculosis organisms carrying by droplet nuclei from an individuals 
with active TB culminate with the phagocytosis by alveolar macrophages in the alveolar space (51). 
The first interaction between Mtb and the host is with the innate immune system and seems to be 
mediated by pattern recognition receptors. Recognition by macrophages and dendritic cells of Mtb through 
mannosylated lipoarabinomannan, trehalose dimycolate, and N-glycolyl muramyl dipeptide triggers innate 
responses and might be important in establishing subsequent host–pathogen interactions (52-54). 
Following infection, different  phagocytic cells, such as alveolar macrophages, neutrophils, and dendritic 
cells (DCs), arrive to the infected site and start to build the organize structure of granuloma (55,56). 
It has been hypothesized that the different host- pathogen interactions in the early step of the infection 
determine a spectrum of granulomas with various capacities to contain and kill the bacteria. Consequently, 
the clinical outcome is strongly influenced by the characteristics of the granuloma (36,37). 
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Within granulomas, Mtb might hides itself from immune-based killing mechanisms and drugs, potentially 
promoting the emergence of drug-resistant strains. The macrophage might also have two mutually 
contradictory roles: activated macrophages are capable of killing or controlling the growth of Mtb, and they 
also provide the primary growth niche for this intracellular organism (33,34). The destiny of infected 
macrophages is to protect the host from Mtb by regulating innate and adaptive immunity. Virulent strains 
of Mtb inhibit apoptosis and trigger macrophage necrosis, thereby evading innate immunity and delaying 
the start of adaptive immune responses (57). 
Recently, several gene expression studies have focused the attention on the neutrophil activity during the 
Mtb infection. It has been demonstrated the presence of a IFN-β signature dependent by neutrophil in 
patients with active TB disease (58,59). Neutrophils were the main cells infected with Mtb in samples of 
human BAL fluid, sputum, and pulmonary cavities from patients with active TB disease (26). Neutrophil 
recruitment plays a causal role in disease progression, with potentially both protective and destructive 
properties, that is likely dependent on their timing and magnitude of response (37). 
Three to eight weeks after initial infection with Mtb, cell-mediated immunity develops. The underlying 
immunology of protection against TB is not fully understood and certainly involves both innate and 
adaptive responses; however, T helper 1 (Th1) cell-mediated immune responses appear to play a major role 
(31,32,60). The initial infection is dominated by a Th1-type immune response; however, if the infection is 
not contained, a gradual shift toward T helper 2 responses occurs (61). Th1 cells are activated and 
proliferate in response to interleukin-12 (IL-12) produced by Mtb-infected macrophages, as well as other 
cytokines released by antigen-presenting cells such as IL-18 and IL-23 (62). Activated Th1 cells are the major 
source of IFNγ, which is crucial for macrophage activation and containment of the infection. At this stage, 
elimination of Mtb before establishment of adaptive immunity is possible; however, Mtb has evolved 
immune evasion mechanisms that allow the bacteria to survive in the host for prolonged periods (32,55). 
Despite the importance of IFN-γ, this cytokine alone is not sufficient for protection. Tumor necrosis factor α 
(TNFα), which induces chemokine secretion from macrophages, is equally important in controlling primary 
infection by supporting the formation of granulomas. Individuals treated with TNFα receptor antagonists 
for rheumatologic diseases frequently suffer from reactivation TB, highlighting the importance of this 
cytokine in containment of mycobacteria (63). Although TNF-α is required for protection, high IL-4 levels 
together with TNF-α appear to promote immunopathology (63). Similarly, IFN-γ and IL-2Rα are present at 
higher levels in bronchoalveolar lavages (BALs) from TB patients with severe disease than in those from 
moderate TB disease cases (64). 
Other T-cell subsets playing an important role during Mtb infection, are Th17 cells, which facilitate the 
recruitment of Th1 cells to the site of disease (65) and regulatory T cells (Tregs), which control excessive 
immunopathology (66,67). 
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Our understanding of immune responses against TB, however, remains incomplete, because, for example, 
the importance of B cells is not well-defined, despite their presence in granulomas (43). Apart from B and T 
cells, other cell subsets also play a role during Mtb infection including myeloid-derived cells. Myeloid-
derived suppressor cells (MDSCs) suppress T-cell function in cancer biology (68) and infectious diseases 
(69), including TB (70). MDSCs are present in higher frequencies and suppress T-cell activation and 
trafficking in TB patients and in individuals recently infected with Mtb (70).  
In summary, there are a variety of cells, cytokines, and molecules present in airways that can modulate the 
initial response of the host to Mtb infection. These factors may prevent infection completely, limit initial 
establishment of granulomas, modulate the local environment of newly emerging granulomas, or increase 
the induction of T cell responses against Mtb. Changes in these factors could increase susceptibility to initial 
infection as well.  
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CHAPTER 2: TUBERCULOSIS BIOMARKERS: FROM DIAGNOSIS TO PROTECTION 
 
 
 
2.1 Abstract 
New approaches to control tuberculosis (TB) worldwide are needed. In particular, new tools for diagnosis 
and new biomarkers are required to evaluate both pathogen and host key elements of the response to 
infection. Non-sputum based diagnostic tests, biomarkers predictive of adequate responsiveness to 
treatment, and biomarkers of risk of developing active TB disease are major goals. Here, we review the 
current state of the field. Although reports on new candidate biomarkers are numerous, validation and 
independent confirmation are rare. Efforts are needed to reduce the gap between the exploratory up-
stream identification of candidate biomarkers, and the validation of biomarkers against clear clinical 
endpoints in different populations. This will need a major commitment from both scientists and funding 
bodies. 
2.2 Introduction 
Tuberculosis (TB) is a communicable infectious disease, spread almost exclusively by coughed aerosols 
carrying pathogens from the Mycobacterium tuberculosis (Mtb) complex. TB is characterized pathologically 
by necrotizing granulomatous inflammation usually in the lung, although almost any extra-pulmonary site 
can be involved. TB remains one of the most significant infectious causes of mortality and morbidity 
worldwide. As reported by the World Health Organization (WHO) it causes disease among 9.6 million 
people each year and ranks alongside the human immunodeficiency virus (HIV) as a leading cause of death 
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worldwide (1). In 2014, 1.5 million TB deaths were reported and among them approximately 140,000 were 
children. The number of TB deaths is unacceptably high because with a well-timed diagnosis and 
appropriate treatment, almost all people with TB can be cured. Therefore all efforts to fight TB must be 
intensified. Additionally, it is estimated that one-third of the world’s population is latently 
(asymptomatically) infected with Mtb, and approximately 3 to 10% of these infected individuals are likely to 
progress to active disease during their life. The risk of reactivation and subsequent disease and mortality is 
significantly increased in individuals with HIV coinfection (2,3) and therapy with TNFa inhibitors (4,5). 
Approaches to decrease TB morbidity and mortality, along with Mtb transmission, rely on effective 
treatment, correct diagnosis, and prevention of infection and disease. 
Effective therapy is central to any strategy for controlling TB and biomarkers that indicate initiation of 
successful treatment could facilitate development of alternative treatment strategies. There is a need for 
shorter treatment regimens to increase compliance. Unfortunately, recent studies have not shown 
definitive results (6-8). In fact, in the REMoxTB Clinical Trials experience, despite early effectiveness 
(superior early bactericidal activity and 2-month culture conversion rates in patients treated with 
moxifloxacin compared to the standard regimen), the 4-month-regimen was less effective than the 
standard 6-month regimen in preventing TB recurrence (6,8). Moreover, correct and efficacious treatment 
is also needed to avoid multidrug-resistant (MDR)-TB. Globally, an estimated 3.3% of new TB cases and 20% 
of previously treated cases had MDR-TB in 2014 (1). This translates into an estimated 480,000 people 
having developed MDR-TB in 2014 with a treatment success rate of only 48%. (1). Patients with MDR-TB 
urgently require treatments that quickly eradicate active infection while preventing emergence of 
additional resistance, which otherwise causes treatment failure and death. 
Accurate diagnosis is also a cornerstone of TB control. Active TB diagnosis is based on the detection of Mtb 
in sputum, which depends on the presence of necrotic infection foci in proximity to the airways. The 
diagnosis then is based on sputum smear and culture, (9-12) and more recently positive GeneXpert 
MTB/RIF tests (13). Microscopy is largely available and highly specific, but lacks sensitivity, missing the 
diagnosis in over one third of patients seeking care (9,14). Mycobacterial culture remains the gold standard 
for TB diagnosis, but provides results only after considerable delay (3-4 weeks). All these diagnostic tests 
require a Mtb-positive sputum while many active TB patients, including HIV-coinfected individuals, diabetes 
patients, and children, often do not present with Mtb positive sputum (15,16). In pulmonary TB a positive 
microbiological diagnosis inevitably means the presence of Mtb in the airway secretions, such that in all 
likelihood Mtb has been already transmitted to others. By definition, sputum diagnostics are not useful in 
extra-pulmonary disease, the diagnosis of which relies on samples (tissue or biological fluids as pleural-, 
cerebral-, synovial-fluids) collected by invasive procedures. For all of these reasons, there is need for the 
development of highly sensitive and specific diagnostic tests for TB to rapidly identify - or rule out - the 
presence of active disease. These tests need to perform in endemic settings with limited laboratory 
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facilities, at low cost, using easily accessible non-sputum based samples such as blood, urine, or breath. 
These are the four high priority target product profiles (TPPs) recently published by the WHO as a result of 
a consensus meeting on new TB diagnostics (17). Therefore the urgent need to search for biomarkers 
(defined as measurable characteristics that indicate normal or pathogenic biological processes, or 
pharmacological responses to therapeutic intervention) (18) needs to be highlighted: biomarkers can serve 
as surrogate endpoints in clinical trials, and can be used to improve treatment outcome by informing 
therapeutic decisions for individual patients (19). Sputum culture conversion using solid medium is the 
best-characterized TB biomarker for successful treatment, having been examined in many studies either as 
a simple measure (e.g. month 2 culture status) or in more complex forms requiring subsequent negative 
cultures (e.g. stable culture conversion). However, as reported above, in the REMoxTB trial patients 
developed recurrent TB despite negative sputum cultures at month 2. Thus better biomarkers predictive of 
TB treatment outcome are needed (20,21). This is a priority for the TB research field and has the potential 
to impact not only research but also clinical practice globally (22-24). 
In this paper we will review most of the recent advances in research into TB biomarkers for the diagnosis of 
active TB, latent TB infection (LTBI) and prevention of TB disease. 
2.3 Biomarkers for diagnosing active tuberculosis 
We may distinguish biomarkers related to the pathogen and to the host (Figure 1). From the pathogen 
perspective, Mtb products could be detected directly in blood, sputum or urine. Mtb DNA can be detected 
in blood and urine of pulmonary TB patients with a better sensitivity than Mtb culture from the same 
biological fluid (25-27). The Mtb cell wall component lipoarabinomannan (LAM) has been proposed as TB 
biomarker; however the available commercial test on urine has a poor sensitivity (28). This can be partly 
enhanced by other LAM assays (29-31). Although unsatisfactory as yet, in HIV-infected patients the Mtb 
DNA and LAM detection in urine may be an important tool to consider especially for those advanced cases 
with low CD4 T-cell counts (32-34). The Mtb Ag85 complex is a 30-32 kD family of three proteins (Ag85A, 
Ag85B, and Ag85C) with enzymatic mycolyl transferase activity involved in the coupling of mycolic acids to 
the arabinogalactan of the cell wall and in the biogenesis of the cord factor (35,36). The detection of Ag85 
in blood and urine, however, shows highly variable performance in different studies (29,37,38). 
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Figure 1 Flow chart of the biomarkers for active tuberculosis diagnosis. TB: tuberculosis; Ag: antigen; LAM: 
lipoarabinomannan; BAL: broncholavage; IP: Interferon-γ inducible protein; FACS: Fluorescence-activated cell sorting. 
Among the host biomarkers, there are various non-sputum based-assays for active TB diagnosis, relying on 
serum, plasma, urine or stimulated or unstimulated blood. Considering serum or plasma products, Mtb 
specific antibody detection is not a promising diagnostic approach due to heterogeneity of the response to 
Mtb (11,39). Moreover WHO negatively advised on the use of such tests for diagnosing active TB disease 
(40). The evaluation of serum micro-RNAs has shown different levels of accuracy for diagnosing active TB in 
drug-sensitive and drug resistant TB (41-44). 
A broad range of potential transcriptional TB biomarkers has been reported. Modular and pathway analysis 
revealed that the neutrophil driven interferon (IFN)-inducible gene profile, consisting of both Type 2 (IFNγ) 
and Type I (IFNαβ) IFN signaling represented a significant TB signature detectable in the peripheral blood 
from pulmonary TB patients (45). These findings have been also validated in other populations, (21,46-50) 
and in several studies could differentiate TB from other respiratory infections and inflammatory diseases 
(24,45,49,51). Moreover it has been shown that disease activity increased the signature whereas treatment 
decreased it (21,22,49). Integrated analysis of gene expression signatures obtained in eight independent 
studies revealed additional pathways that are likely to contribute to discrimination of TB disease from other 
diseases (52). Diagnostic signatures to distinguish TB from other diseases and from LTBI were also found in 
children from South Africa, Malawi and Kenya (53). However one of the major challenges in the evaluation 
of new childhood TB diagnostic is the lack of a reference, due to the difficulty of microbiological diagnosis 
of active disease. Taking all these studies together it is important to mention that the minimum TPP 
requirements are not yet satisfied in terms of sensitivity and specificity. The complexity of the analysis and 
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the expensive molecular techniques related to the transcriptional profiles make it currently difficult to be 
used as routine diagnostic tests unless easier technologies are developed (52). However, all studies 
reported above are important for our comprehension of TB pathogenesis. 
The interferon (IFN)γ inducible protein 10 (IP10) was found to be increased in the unstimulated plasma of 
children and adults with active TB, (54-58) and has been evaluated by different methodologies including 
also innovative technologies based on lateral flow assays using the interference-free, fluorescent up 
converting phosphor (UCP) labels in multicenter studies conducted in Africa (59-63). Interestingly, IP10 can 
be also detected in the urine of adult patients (64), Ugandan children with active TB (58), and IP10 levels 
decreased after efficacious therapy (64). In comparison with blood, urine biomarkers offer the advantage of 
non-invasive sample collection, especially in children, and also pose lower bio safety risks for health care 
workers. 
Flow-cytometry has been proposed as a potential tool to help improving TB diagnosis. Advancement in 
multiparametric flow cytometry allows the simultaneous evaluation of several immune functions in single 
cells such as cytokine production and memory status. Polyfunctional T-cells, cells able to produce more 
than one cytokine simultaneously, have been described as part of immune response to different pathogens 
such as viruses, bacteria and worms (65-68). Moreover T-cells coproducing IFNγ, TNFα and IL2 have been 
associated with protective T-cell immune responses in HIV non-progressors subjects (67). Studies 
evaluating the role of polyfunctional T-cells in TB did not show consistent results. Active TB has been 
associated with either monofunctional TNFα+CD4+ T-cells (69), or double functional IFNγ+TNFa+ CD4+ T-
cells(70-73), or triple functional IFNγ+TNFα+IL2+ CD4+ T-cells (74). By contrast, studies on activation and 
memory status of Mtb-specific T-cells seem to be more consistent, even when comparing patient 
populations enrolled at different sites or using different experimental settings. Effector T-cells expand 
during active Mtb replication, whereas memory cells associate with control and eradication of Mtb 
infection (71,72,75-78). In particular, it has been shown that active TB is associated with a decrease in CD27 
surface expression on circulating Mtb-antigen stimulated CD4+ T-cells (70,77,79-81). Recently, a novel T-
cell activation marker-TB (TAM-TB) assay was described for diagnosis of active TB in children (80). The TAM-
TB assay has been validated in an adult population in Tanzania and is based on the ratio of the median 
fluorescence intensity of all CD4+CD27+ T-cells over the median fluorescence intensity of Mtb-specific 
CD4+CD27+ T-cells (CD27 MFI ratio). This approach has also been tested in an adult population from a low 
TB endemic country and confirmed discrimination between different stages of TB infection (77). 
Another interesting blood-based study showed that the expression of immune activation markers CD38 and 
HLA-DR and proliferation marker Ki-67 on Mtb-specific CD4+ T-cells associated with Mtb load. The 
modulation of these markers accurately distinguishes active from LTBI with 100% specificity and over 96% 
sensitivity. These markers also correctly classified individuals who had successfully completed TB therapy, 
indicating a correlation with the decrease in mycobacterial load following treatment (82). Interestingly, 
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recently the T-cell activation has been described also as an immune correlate of risk for TB development in 
BCG-vaccinated infants (83). 
Among the untargeted discovery approaches to identify new markers for TB patients’ stratification, the 
transcriptomic, proteomic, or metabolomic approaches have been used (43,84). In particular Tientchieu et 
al. evaluated the transcriptomic and metabolic profiles of subjects infected with two different lineages of 
Mtb, the M. africanum (Maf) and Mtb before and after anti-TB therapy to access the differences in host 
factors and/or biological processes associated with disease pathology and response to treatment. 
Peripheral blood gene expression profiles were not different between Maf- and Mtb-infected patients pre-
treatment but differed significantly post-treatment, and these were mainly associated with immune 
responses and metabolic diseases. Notably, the upstream regulator hepatocyte nuclear factor 4-α 
regulated about 15% of the genes differentially expressed between the groups post-treatment. The serum 
metabolic profiles were similar between Maf- and Mtb-infected patients both pre- and post-treatment, but 
significantly different between pre- and post-treatment, particularly in Mtb- than in Maf-infected groups. 
Using different approaches, as the mass spectrometry or protein chip technology, it is possible to have a 
proteomic profiling of many peptides when comparing TB patients and healthy subjects. Analysis of sera for 
host markers showed that transthyretin, C-reactive protein and neopterin might discriminate TB patients 
from subjects with other infectious and inflammatory conditions with high accuracy (85). Similarly, sputum 
may also be used to analyze proteomic profiles, as data on smear-negative vs. smear-positive TB patients 
were significantly different from those found in control subjects (86). 
Volatile organic compounds (VOCs) in breath may contain biomarkers of active pulmonary TB derived 
directly from the infectious organism (e.g. metabolites of Mtb) and/or from the infected host (e.g. products 
of oxidative stress). A breath test based on the detection and quantification of VOCs identified potential 
biomarkers of active pulmonary TB with 85% accuracy in symptomatic high-risk subjects (87). However, 
detection of VOCs is technically difficult because most breath VOCs is excreted in picomolar concentrations 
(parts per trillion), and most analytical instruments currently used cannot detect VOCs at such low 
concentrations. 
 
2.4 Biomarkers to monitor tuberculosis therapy efficacy 
The absence of satisfactory tools for monitoring TB therapy efficacy impedes optimal clinical management 
of patients, especially for extra-pulmonary TB where it is not possible to detect Mtb in sputum, (88,89) 
precluding the possibility to make a link between sputum culture and clinical outcome. The majority of 
publications investigating treatment response biomarkers failed to articulate the intended use and 
underlying TPP. Furthermore, most studies compared changes in proposed biomarkers over time during 
treatment without testing, or being powered to test, the correlation with patient outcome, i.e., relapse-
free cure (Figure 2). Study comparisons of Xpert MTB/RIF, smear microscopy and culture using both solid 
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and liquid media have shown that the Xpert MTB/RIF assay has high sensitivity (97%) but poor specificity 
(49%) to identify culture positive specimens when Xpert is used as a binary readout. The quantitative 
measurement from the Xpert MTB/RIF assay, showed that the change in quantitative sputum bacterial load 
correlated with smear grades, solid culture grades, and time to liquid culture positivity (90). This 
quantitative data may be used in the future to predict clinical outcome of patients. Considering that the 
Xpert MTB/RIF test detects DNA from dead as well as live Mtb, a recent study proposed to perform the 
quenching of DNA detection from dead mycobacteria by adding propidium monoazide (which quenches 
PCR-mediated detection of DNA from dead mycobacteria) to specifically detect only viable bacilli (91). This 
test seems promising since a positive correlation with time to positivity of Mtb cultures on liquid media was 
reported. Concerning the host side, the development of biomarkers able to monitor Mtb load is still far 
from reality. Recently, Cliff et al. reported that cytotoxic cell gene expression signatures, expressed at 
diagnosis might predict disease relapse after initial successful cure (sputum conversion), indicating that 
host factors are important indicators of treatment success (22). The first profiles of a response to TB 
therapy were reported by Joosten et al (23). These promising data need to be confirmed in large-scale 
studies. Many efforts have evaluated different proteins in e.g. serum or plasma samples. It has been shown 
that plasma vascular endothelial growth factor (VEGF) (92) concentrations at 2 weeks of therapy correlated 
positively with time to sputum conversion. Similarly, hemeoxygenase-1 (HO-1) and matrix 
metalloproteinases (MMPs) levels correlated with clinical outcome of pulmonary TB, although contrasting 
findings were reported (93). This is likely due to the inhibition of MMP by CO, a product of Mtb-induced 
HO-1 activity, observed in vitro after infection with Mtb in human macrophages (94). Other factors as IL11 
receptor antagonist, 2-antiplasmin, proteasome activator complex subunit 1, and serum amyloid A 
predicted sputum conversion with an estimated 80% sensitivity and specificity (95). 
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Figure 2: Flow chart of the biomarkers to monitor TB therapy efficacy. TB: tuberculosis; Ag: antigen; LAM: 
lipoarabinomannan; VEGF: vascular endothelial growth factor; BAL: broncholavage; IP: Interferon-γ inducible protein; 
FACS: Fluorescence-activated cell sorting; IL: interleukin; PSME1: proteasome activator complex subunit 1; SAA: serum 
amyloid A; PET/CP: positron emission tomography/computed tomography. 
The chemokine IP10 that has increased in the unstimulated plasma of children and adults with active TB 
has also been measured in dry plasma spots as biomarker for therapy response (54-58,96). In addition, IP10 
kinetics in the first week of TB therapy has been proposed as a tool to confirm a clinical diagnosis and guide 
specific therapy (97). 
Radiological severity has been classified with different scores to predict treatment outcome in adults with 
pulmonary TB using different tools (98,99). High-resolution 3-dimensional imaging helps evaluating the 
pulmonary TB burden during therapy (100). In the lungs, a quantitative volumetric change in the uptake of 
2-deoxy-2-[18F)-fluro-D-glucose (FDG) after 2 and 6 months of TB therapy has been detected by positron 
emission tomography/computed tomography (PET/CT) quantification and this modulation could be 
correlated with treatment outcome. However, due to machine equipment, complexity, cost and radiation 
exposure, the use of PET/CT approach is still restricted to clinical trials. As reported above modulation of 
CD27 evaluated by flow cytometric studies may be a novel marker not only for active TB diagnosis but also 
therapy monitoring (70,77,80,81). The same may hold true for the modulation of CD38, HLA-DR and 
proliferation marker Ki-67(82). 
In analogy to cancer, an expansion of myeloid derived suppressor cells (MDSCs), which have a remarkable 
ability to suppress T-cell responses (101,102), has been observed in the lung and blood of patients with 
active TB whereas a contraction is reported after efficacious anti-TB therapy (102). 
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TB therapy significantly decreased the in vitro IFNγ response induced by peptides selected from ESAT-6 and 
CFP-10 in patients with active TB in studies conducted in Europe (103,104), Uganda (105) and India (106), 
suggesting that this response can be a tool to monitor anti-TB treatment efficacy. The results have been 
confirmed using IP10 instead of IFNγ (106,107). 
 
2.5 Biomarkers for latent tuberculosis infection identification 
Using a clinically pragmatic approach, LTBI is defined by the presence of a specific immune response 
detected by an IFNγ release assay (IGRA) or the tuberculin skin test (TST) (Figure 3) in the absence of lung 
lesions of active TB in xRay images, in individuals from whom it is not possible to isolate Mtb (108), 
IGRA(QuantiFERON TB Gold in tubes (Qiagen, Venio, the Netherlands; QFT-GIT) and T-SPOT.TB (Oxford 
Immunotec, Marlborough, MA, USA)) measure in vitro IFNγ production by whole blood ELISA (109) or an 
enzyme-linked immunospot (ELISPOT) (110) assay on peripheral blood mononuclear cells (PBMC), 
respectively (109,110). Blood is stimulated with Mtb-specific antigens (111), which are deleted from the 
genome of M. bovis BCG and are not present in most environmental mycobacteria (112-115). TST is based 
on skin infiltration caused by intradermal injection of purified protein derivative (PPD), which is a crude 
mixture of antigens many of which are shared by Mtb, M. bovis, BCG and several species of environmental 
mycobacteria. A particular benefit of in vitro testing is that there is a laboratory test with negative and 
positive controls, and that one visit suffices. In contrast to the TST, these in vitro tests may discriminate 
true negative responses from energy (116). Recently an updated version of the QFT-GIT has been launched 
(https://www.qiagen.com/it/about-us/press-releases/pressreleaseview?id=%7Bc861949e-df50-475b-8148-
b4c70034c49e%7D&lang=en). 
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Figure 3: Flow chart of the biomarkers for LTBI identification: LTBI: latent tuberculosis infection; TST: tuberculin skin 
test; IGRA: IFNγ release assay; Interferon-γ inducible protein; IL: interleukin; PSME1: proteasome activator complex 
subunit 1; EGF: endothelial growth factor; MCP: monocyte chemoattractant protein; TLR: toll like recepetors; sCD14: 
soluble CD14; FACS: Fluorescence-activated cell sorting; ICS: intracellular staining. 
Results from ongoing studies will show if the test has a better accuracy compared to the old QFT-GIT(117). 
It should be noted that both TST and IGRAs share limitations: a low accuracy in immune-compromised 
patients, impossibility to distinguish between LTBI and active disease, which is a major issue in TB endemic 
areas, and low predicting values for active TB diagnosis (118-119). 
Several efforts have been undertaken to distinguish LTBI from active TB, with no clear success probably due 
to the fact that LTBI is characterized by a high heterogeneity of TB lesions that may depict as a broad 
spectrum of conditions that overlap in part with those seen in active disease (120). Some subjects show 
only the remnant of a waning infection, while others show a slowly progressing form of disease, or a 
chronic non-progressing infection (120). 
In the QFT-GIT format the chemokine IP10 has been suggested as an alternative marker for IFNγ (106,121-
123) with high accuracy in the HIV-infected patients (122,124,125). 
Besides IGRA, several approaches for LTBI identification have been proposed: evaluation of plasma 
concentrations of epidermal growth factor fractalkine, IFNγ, IL4, monocyte chemoattractant protein 
(MCP)3, IP10 (126); evaluation of serum pro-inflammatory cytokines IL6, IP10, MCP1 (127); detection of 
plasma levels of markers involved in the Toll-like receptor 4 pathway, like soluble CD14 and myeloid 
differentiation-2(128). A recent study on LTBI subjects demonstrated that Mtb-specific CD4+ T-cells have a 
characteristic chemokine expression signature (CCR6+CXCR3+CCR4-), and that the frequency of these cells 
is increased in LTBI subjects compared with healthy donors (129). This study suggested a possible role of 
specific subsets of CD4+ T-cells in the containment of Mtb and raises interesting questions on the possible 
role of these cells. In particular the transcriptional profile of CCR6+CXCR3+CCR4-CD4+ T cells revealed 
characteristics important for TB containment, since gene expression profiles correlated with TB 
susceptibility genes, enhanced T-cell activation, cell survival and cytotoxic response (129). Stimulation with 
the so called Mtb latency antigens, such as Rv1733c, Rv2029c, Rv2628 and HBHA (130-136) seem promising 
tools to identify LTBI subjects and distinguish recent LTBI from remote LTBI (130,137,138). If confirmed in 
larger studies, these results may have important implications for risk stratification when deciding to initiate 
preventive therarpy (130,138,139). 
 
2.6 Biomarkers for prevention: vaccine studies 
 
As discussed above, among the T-cell based biomarkers, polyfunctional T-cells have been explored as 
potential biomarkers by multiparametric flow technology. In animal models, i.e. mice, vaccine-induced 
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protection against Mtb infection strongly correlated with a high frequency of polyfunctional CD4+ T-cells 
(140,141). However the correlation of this polyfunctional cytokine profile with protective efficacy of BCG 
vaccination was absent in humans, as reported in a cohort of BCG-immunized infants monitored for 2 years 
(142). Similar results were obtained in a TB vaccine study based on MVA85A (modified vaccinia virus Ankara 
expressing antigen 85A) (143). In addition, polyfunctional T-cells have been reported at increased 
frequencies in active TB (74). These studies suggest that polyfunctional T-cells play a role in vaccine induced 
protection against TB in animal models, but do not represent a correlate of BCG-induced or natural 
protection in humans, as they are also present in active TB (74,144) Th17 cells are capable of providing 
protection in immunization and cellular transfer mouse models (145-147). Th17 cells are long lived and can 
become memory cells, despite expressing markers characteristic of terminally differentiated cells (148) and 
have self-renewal capacities (149). Th17 cells preserve the molecular signature that is characteristic of T 
stem cell memory (TSCM)(150-152). IL17 seems to play an important role in Mtb protection. It has been 
shown that mice lacking IL17A receptor, despite being able to control acute infection, are unable to stably 
maintain long-term control of Mtb infection (153). This is due to decreased early neutrophil recruitment, 
more than IFNg deficiency. Recently it has been shown that the requirement for IL17 in host protection 
against Mtb in the mouse model is Mtb strain dependent. IL17 was dispensable for protective immunity 
against the lab-adapted strain H37Rv while necessary for protection against Mtb HN878, a hypervirulent 
Mtb strain (154). IL17 is important in vaccine-mediated protection in TB. Following BCG and ESAT-6 peptide 
immunization (155,156), antigen-specific Th17 cells localized in the lungs and were critical for the 
recruitment of Th1 cells to the lung after Mtb challenge. Innate immune responses are conventionally 
thought to provide immediate protection before the adaptive immune response is generated, thus 
contributing towards early containment of the pathogen. However, a growing number of studies suggests 
their involvement in the recall response and protection during secondary challenge, as shown by the 
generation and long-term maintenance of NK cells in response to viral infections such as those with 
cytomegalovirus (CMV) and hepatitis C virus (HCV) (157).There are studies ongoing to evaluate the role of 
NK memory cells in Mtb protection. γδT-cells recognize a variety of unrestricted, unprocessed and small 
phosphate antigens (158). In the mouse model, during the early phase of infection with Mtb, γδT-cells 
secreting IFNγ and IL17 with cytotoxic effector functions are recruited to the lungs (159). Expansion of γδT-
cells in response to BCG vaccination and their presence in Mtb-specific recall response are also reported in 
the nonhuman primate macaque model.160 In addition, γδT-cells reduce the viability of intracellular Mtb 
via mechanisms dependent on perforin or granulysin (161,162). These data, together, indicate not only that 
γδT-cells are present during Mtb infection and following BCG vaccination but that, in humans, they are 
capable of restricting Mtb growth. Also many other components of the innate immune system participate 
in the control of Mtb infection, but this is beyond the scope of this brief review (144). 
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2.7 Conclusions 
There is a pressing need for new biomarkers in TB at all different levels discussed above (144,163). Though 
studies on new candidate biomarkers are numerous, validation and independent confirmation are rare, 
unfortunately. Efforts are needed to reduce the gap between the exploratory up-stream identification of 
candidate biomarkers, the validation of biomarkers against clear clinical endpoints in different populations, 
and the development of simple point of care tests for use in low resourced settings (20). This needs 
important commitment from both researchers and economic funders. 
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CHAPTER 3: CORRELATES OF TUBERCULOSIS RISK: PREDICTIVE BIOMARKERS FOR PROGRESSION TO 
ACTIVE TUBERCULOSIS 
 
 
3.1 Abstract 
New approaches to control the spread of tuberculosis (TB) are needed, including tools to predict 
development of active TB from latent TB infection (LTBI). Recent studies have described potential 
correlates of risk, in order to inform the development of prognostic tests for TB disease progression. These 
efforts have included unbiased approaches employing “omics” technologies, as well as more directed, 
hypothesis-driven approaches assessing a small set or even individual selected markers as candidate 
correlates of TB risk. Unbiased high-throughput screening of blood RNAseq profiles identified signatures of 
active TB risk in individuals with LTBI, ≥1 year before diagnosis. A recent infant vaccination study identified 
enhanced expression of T-cell activation markers as a correlate of risk prior to developing TB; conversely, 
high levels of Ag85A antibodies and high frequencies of interferon (IFN)-γ specific T-cells were associated 
with reduced risk of disease. Others have described CD27−IFN-γ+CD4+ T-cells as possibly predictive markers 
of TB disease. T-cell responses to TB latency antigens, including heparin-binding haemagglutinin and DosR-
regulon-encoded antigens have also been correlated with protection. 
Further studies are needed to determine whether correlates of risk can be used to prevent active TB 
through targeted prophylactic treatment, or to allow targeted enrolment into efficacy trials of new TB 
vaccines and therapeutic drugs. 
3.2 Introduction 
Tuberculosis (TB) is the most significant infectious cause of mortality and morbidity worldwide. As reported 
by the World Health Organization (WHO), there are 10.4 million new cases of TB each year(1). TB is a 
communicable disease, transmitted almost exclusively by cough aerosols carrying pathogens of the 
Mycobacterium tuberculosis complex. Pathogenesis is characterised by a period of asymptomatic 
subclinical infection, defined broadly as latent tuberculosis infection (LTBI), which might last for weeks or 
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decades. From an operational point of view, LTBI may best be defined as a state of persistent immune 
response to M. tuberculosis antigens detected either by the tuberculin skin test (TST) or by interferon (IFN)-
γ release assay (IGRA) without evidence of clinically manifest TB. Based on this definition, individuals with 
LTBI carry an increased risk of progression to TB. However, an unknown but large proportion of those with 
LTBI will not develop TB, either because their immune system persistently controls mycobacterial 
replication or because they are no longer infected with live bacteria. The risk of reactivation and 
subsequent disease and mortality is significantly increased in M. tuberculosis-infected individuals with 
immune suppression, due to HIV co-infection(2) or therapy with tumour necrosis factor (TNF)-α 
inhibitors(3–6), or other immune regulators used for inflammatory diseases and transplantation(7) or 
compromised immunity due to noncommunicable diseases, such as type 2 diabetes(8, 9). Approaches to 
decrease TB morbidity and mortality, along with M. tuberculosis transmission, rely on correct diagnosis, 
effective treatment and prevention of infection and disease. Until recently, LTBI was thought to represent a 
uniform state(10). However, it has become clear that LTBI has to be considered a broad spectrum of 
infection states that differ by the degree of the pathogen replication, host resistance and inflammation(10–
13). Similarly, TB disease presentation is similarly diverse and heterogeneous. This heterogeneity includes 
the type of pathology developed in the lungs ( pulmonary TB) or outside the lungs (extrapulmonary TB), the 
spread of the lesions, the characteristics of immune activation and inflammation, M. tuberculosis 
replication and bacterial load. An increasing body of evidence supports the hypothesis that the genetic 
background of the host influences TB disease manifestations and the success of the bacterium in infecting 
large numbers of susceptible individuals(14–17). An important hurdle in the field of TB research is that the 
bacteria cannot be directly detected in vivo during latent, asymptomatic M. tuberculosis infection. A test 
that could quantify bacterial numbers or levels of replication during LTBI would advance our ability to 
define the stages of infection, and allow more detailed studies of pathogenesis and immunity during 
asymptomatic M. tuberculosis infection. Outcome of M. tuberculosis infection is therefore not a simple 
two-state distribution represented by either LTBI or active TB, but rather represents a continuous spectrum 
of states that differ by pathogen and host “activity”, which require different diagnostic and treatment 
strategies (figures 1 and 2). 
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FIGURE 1 Outcome of Mycobacterium tuberculosis transmission and establishment of infection or disease based on 
the correlates of disease and correlates of risk. The outcome of a primary or secondary M. tuberculosis infection is 
not a simple two-state distribution represented by either active tuberculosis (TB) or latent TB infection, but rather 
represents a continuous spectrum of states that differ by the degree of the pathogen replication, host resistance and 
inflammatory markers. The identification of M. tuberculosis infection is complex, due to the absence of clinical signs, 
correlates of disease (COD), lung lesions detected by chest radiography or M. tuberculosis in the sputum culture. The 
latency state is characterised by an immunological equilibrium and by presumed control of the bacterial replication. 
As the infection advances, this balance is lost, resulting in increased bacterial burden and/or increased pathology. This 
state can be identified as subclinical or incipient TB disease, in which CODs may still be poorly informative. In contrast, 
correlates of risk (COR) may potentially allow the identification of those at risk, for preventive treatment. Indeed, 
upregulation of interleukin (IL)-13 and type I and II interferon (IFN)-related gene expression, elevated activation 
markers on T-cells (e.g. expression of D-related human leukocyte antigen and loss of CD27 expression), as well as an 
elevated monocyte/lymphocyte (M/L) ratio, have been shown to be predictive of TB disease development. The 
progression of subclinical TB to clinical TB is likely to be associated with a further increase in bacterial burden and/or 
pathology. Therefore, active TB diagnosis is based on CODs, including chest radiography findings such as lung lesions 
indicative of disease, detection of M. tuberculosis in sputum and positive COR tests. Transmission of M. 
tuberculosis from active TB patients may lead to a primary or secondary M. tuberculosis infection. Primary M. 
tuberculosis infection is defined by IFN-γ release assay (IGRA)/tuberculin skin test (TST) conversion and absence of 
radiological lung lesions and sputum negative for M. tuberculosis. ↓: downregulation; ↑: upregulation; +: presence of 
a modulation based on current knowledge; −: absence of a modulation based on current knowledge. 
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FIGURE 2 Correlates of tuberculosis (TB) disease, infection and risk of disease. Evaluation of tests to detect active TB 
disease, subclinical TB disease, incipient TB disease, infection and cleared infection. M. tuberculosis: Mycobacterium 
tuberculosis; TST: tuberculin skin test; IGRA: interferon-γ release assay; COR: correlates of risk; M/L: 
monocyte/lymphocyte 
 
From both a clinical and a research point of view, it would be important to correctly identify those M. 
tuberculosis-infected individuals who are most likely to progress to active disease in order to target them 
precisely with preventive treatment(18, 19). Prevention of TB disease arising from latent infection is key to 
achieving WHO elimination targets(18, 20, 21), yet mass preventive therapy based on IGRA/TST screening 
in TB-endemic countries would need to treat 50–80% of the population, most of them unnecessarily, since 
85–95% of latently infected persons will never develop disease in their lifetime(22–24). The positive 
predictive value of IGRA/TST testing is thus too low, and better prognostic tests are required. The TST and 
IGRA tests are based on immunological sensitisation to mycobacterial antigens. In the case of the TST this is 
quantified by the transverse diameter of skin induration resulting from intradermal injection of purified 
protein derivative, a crude mixture of antigens, many of which are shared by M. tuberculosis, M. bovis, 
bacille Calmette–Guérin (BCG) and several species of environmental mycobacteria. Blood-based IGRA, 
including QuantiFERON TB Gold in-tube (QFT-GIT; Qiagen, Hilden, Germany) and T-SPOT.TB (Oxford 
Immunotec, Abingdon, UK), measure in vitro IFN-γ production upon antigen stimulation of whole blood 
using ELISA, or peripheral blood mononuclear cells (PBMCs) using enzyme-linked immunospot (ELISPOT) 
assay, respectively(25). In these assays, specificity for M. tuberculosis is derived from stimulation with 
peptides spanning the M. tuberculosis antigens ESAT-6, CFP-10 (and TB7.7 for QFT-GIT) that are restricted 
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to a region of the M. tuberculosis genome deleted from M. bovis BCG and which is not present in most 
environmental mycobacteria(26–29). A practical benefit of IGRA tests is that they require only a single 
laboratory test with negative and positive controls, and only one visit. Moreover, the in vitro tests may 
discriminate true negative responses from anergy(25). An updated version of the QFT-GIT has been 
launched(25, 30): the QuantiFERON TB Plus includes an additional antigen tube to QFT-GIT, which contains 
peptides that are intended to specifically induce a CD8+ T-cell response in addition to the CD4+ T-cell 
response(31) detected with the original QFT-GIT assay(32). The rationale for the inclusion of these new 
CD8-specific peptides is derived from the growing evidence that M. tuberculosis-specific CD8+ T-cells are 
more frequently detected in subjects with active TB disease compared to LTBI(33–36), they are associated 
with a recent exposure to TB(37) and they decline when patients receive anti-TB treatment(38). The first 
data on performance of QuantiFERON TB Plus in a multicentre European study were reported recently(39, 
40). Additional promising tests for LTBI detection should be mentioned. C-Tb is a skin test(41) that 
measures hypersensitivity to recombinant ESAT-6 and CFP-10 proteins following intradermal 
administration. The authors claim that it combines the strengths and advantages of TST and IGRA 
technologies: low cost and for ease of use, like the TST, and high specificity analogous to IGRAs. Another 
test, based on Rv3615c encoded outside the RD1 region, has shown potential as a new T-cell based 
immunodiagnostic(42). However, it should be noted that the TST and IGRAs share limitations. They both 
suffer from low accuracy in immune-compromised patients and cannot distinguish between LTBI and active 
TB disease(25). The latter is a major issue in TB-endemic areas and leads to poor predictive value for the 
development of TB in persons with LTBI(25, 43, 44). These limitations provide a compelling reason why a 
simple measure of IFN-γ response does not allow correct evaluation of risk of progression from latency to 
active disease. It follows that the discovery of biomarkers that can differentiate between active and 
quiescent bacterial replication in persons with LTBI, or host markers that identify those with LTBI who are 
at risk of developing active disease(11, 45, 46) is of great importance. Moreover, it is critical that newly 
identified markers and signatures are validated in different geographic settings, because human 
populations with different genetic backgrounds and environmental influences, as well as different 
circulating M. tuberculosis lineages may be associated with variable rates of progression to TB disease(47). 
The characteristics of new prognostic tests that predict progression from latent to active TB disease have 
recently received much attention. In 2015, the WHO convened an expert group to discuss the target 
product profile (TPP) of such a test under the lead of FIND, based on currently available knowledge. For 
such a test to have utility in high TB-burden settings, it should ideally be based on a sample type more 
easily accessible than sputum. While a high positive predictive value (PPV; >95%) for progression from 
infection to active TB (figures 3 and 4) would be ideal, such a high value is probably unachievable in the 
short term, and a more realistic goal has to be considered. The performance characteristics presented here 
and in figures 3 and 4 represent expert opinion (a draft version of the TPP is published on the FIND website: 
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www.finddx.org/wp-content/uploads/2016/05/TPP-LTBIprogression.pdf ) that is undergoing validation in a 
survey of global stakeholders. A sensitivity and specificity of >90% (and minimally 75% for both) were 
considered an appropriate target to obtain acceptable positive and negative predictive values. 
 
 
FIGURE 3 Number of patients needed to treat (NNT) to prevent one case of tuberculosis (TB) for the currently 
available, novel and envisioned diagnostic tests. If we assume a 2-year cumulative TB incidence of 2% and an 
effectiveness of isoniazid preventive treatment of 50%, for the optimal target the NNT would be 13. Similarly, in the 
same scenario, for the minimal target the NNT would be 40. If we evaluate the same parameters for the current 
generations of interferon-γ release assays (IGRA) (based on performance characteristics of IGRA for predicting 
progression of TB as outlined in World Health Organization latent TB infection guidelines(48, 49)), the NNT is 85. TST: 
tuberculin skin test; COR: correlate of risk for TB development; TPP: target product profile. 
 
 
FIGURE 4 Positive predictive value (PPV) to identify cases who have latent tuberculosis (TB) and will develop active 
TB identified by currently available, novel and envisioned diagnostic tests. If we assume a 2-year cumulative TB 
incidence of 2% and an effectiveness of isoniazid preventive treatment of 50% the optimal PPV is 16%. Similarly, in the 
same scenario, for the minimal target the PPV is 6%. If we evaluate the same parameters for the current generations 
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of interferon-γ release assays (IGRAs) (based on performance characteristics of IGRA for predicting progression of TB 
as outlined in World Health Organization latent TB infection guidelines(48, 49)), the PPV is 2–3%. In parallel to the 
development of the target product profile (TPP), a framework for the validation of such tests is being formulated(50). 
TST: tuberculin skin test; COR: correlates of risk for TB development. 
 
If we assume a 2-year cumulative TB incidence of 2% and an effectiveness of isoniazid preventive treatment 
of 50% (figures 3 and 4) for the optimal target the number of patients needed to treat (NNT) would be 13 
with a PPV of 16%. Similarly, in the same scenario, for the minimal target the NNT would be 40 (figure 3) 
with a PPV of 6% (figure 4). If we evaluate the same parameters for the current generations of IGRAs (based 
on performance characteristics of IGRAs for predicting progression of TB as outlined in WHO LTBI 
guidelines(48, 49), the PPV is 2–3% and NNT is 85). In parallel to the development of the TPP, a framework 
for the validation of such tests is being formulated(50). Of course it is important to recognise that the 
performance characteristics of such new prognostic tests (i.e. PPV and NPV) will depend on the underlying 
prevalence of M. tuberculosis infection, the incidence of TB disease and the risk group. Recent research 
activities have aimed at developing correlates of risk of TB, which are likely to inform the future 
development of prognostic tests. These efforts have included unbiased approaches employing “omics” 
technologies, as well as more directed, hypothesis-driven approaches that assessed either a small set or 
even individual selected markers as candidate correlates of risk (COR) of TB (table 1). In the following 
sections we describe some of the most promising approaches. 
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3.3 Blood transcriptomic correlates of risk  
The COR of TB in the most advanced stages of development is a whole-blood transcriptomic mRNA 
expression signature that was identified by mining RNA-sequencing data in a large prospective cohort of 
adolescents with LTBI from South Africa(51). The RNA signature was discovered in a set of 46 progressors 
and 107 controls, and is based on a classifier that computes a TB risk score from relative expression levels 
of 63 mRNA transcripts from 16 genes in whole blood(52). The 16-gene transcriptomic COR signature 
predicted progression from infection to TB disease with a sensitivity of 66% and a specificity of 81% in the 
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12 months preceding diagnosis of incident TB disease in the test cohort. Measurement of the 16-gene 
transcriptomic COR was transferred from measurement of mRNA expression by RNA sequencing 
(HiSeq2000; Illumina, San Diego, CA, USA) to a high-throughput, microfluidic, real-time PCR platform to 
allow cheaper and simpler measurement of gene expression. The PCR-based 16-gene transcriptomic COR 
signature was validated by blind prediction in two independent cohorts of South African and Gambian 
progressors and controls from a prospective household TB contact study, GC6–74 (the Biomarkers for TB 
consortium)(52). In the validation cohorts the sensitivity was 54% and the specificity 83%. Ongoing analyses 
are under way to explore the biological processes that underlie progression in the adolescent study. 
However, it is notable that the 16 genes that comprise the COR signature are all regulated by type I and II 
IFNs, suggesting that chronic peripheral activation of the IFN response, previously shown to be associated 
with active TB disease at the time of diagnosis(53–56), also precedes the onset of active TB disease. 
3.4 Application of correlates to clinical trials and prevention strategies 
 Further development of this PCR-based 16-gene transcriptomic COR included assessment of diagnostic 
performance against published microarray data from TB patients and healthy controls. In a set of HIV-
uninfected South African adults including 130 prevalent TB cases and 230 controls, combined from four 
published studies(53–56), the COR discriminated between active TB and healthy controls with 87% 
sensitivity and 97% specificity. Therefore, although the prognostic 16-gene transcriptomic COR was not 
originally developed for diagnostic purposes, these performance characteristics suggest the signature has 
excellent potential as a nonsputum-based triage test to trigger investigation for undiagnosed TB disease. 
Thus, the 16-gene transcriptomic COR has potential to identify individuals at high risk of undiagnosed TB 
disease at the time of screening and in addition, if active disease has been excluded, to identify individuals 
at high risk for progression to incident TB disease within 12–18 months of screening. These performance 
characteristics would be ideal for a nonsputum-based triage test to identify persons for definitive, sputum-
based investigation; and to identify those persons who would benefit maximally from targeted preventive 
therapy, thus avoiding unnecessary treatment of persons with LTBI who would remain healthy. Prevalence 
of COR+ status in young HIV-uninfected South Africans is ∼12%, and is not different between IGRA-negative 
and IGRA-positive persons (Penn-Nicholson A and Scriba TJ, Cape Town, South Africa; personal 
communication). Given these criteria, screening with the 16-gene transcriptomic COR would allow several-
fold reduction in the number of people requiring COR-targeted preventive therapy in high TB burden 
settings, compared to IGRA-targeted prevention strategies (figures 2 and 3). The ideal COR-targeted 
preventive therapy regimen would be short, safe, sterilising and able to be rolled out rapidly with high 
coverage in serial mass campaigns. A clinical trial to test the efficacy of a 3-month short-course, once-
weekly, high-dose, directly-observed regimen of isoniazid and rifapentine (3HP) for 16-gene transcriptomic 
COR-positive persons without active TB disease started in October 2016 (clinicaltrials.gov/NCT02735590). 
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In parallel, efforts are ongoing to transfer COR testing to a point-of-care device that would allow mass COR 
screening by local healthcare providers. Translation to a point-of-care test may require a more 
parsimonious signature and efforts are underway to reduce the 16-gene transcriptomic COR to a smaller 
set of mRNA transcripts (Scriba TJ et al., Cape Town, South Africa; personal communication). Whole-blood 
transcriptomic signatures for diagnosis of TB disease comprising either three(57) or four genes(58) have 
recently been validated, providing proof of concept that very small sets of genes have potential for 
promising diagnostic utility. If successful, the CORTIS trial will provide proof of concept for the potential of 
community-wide COR screening campaigns to target curative and preventive therapy for those individuals 
at highest risk of TB disease, and impact the global epidemic through early diagnosis and interruption of 
transmission (table 1). Prediction of TB disease months before the onset of clinical symptoms in HIV-
infected persons using host biomarker profiles was first demonstrated in a unique longitudinal cohort as 
part of the Amsterdam cohort studies(59–61). HIV-infected, intravenous drug users had regular blood 
collections at municipal health services and the archive of these samples allowed selection of PBMCs 6 
months to 1 year before the clinical diagnosis of TB. Gene expression profiling using dual-color reverse 
transcriptase multiplex ligation-dependent probe amplification(62) revealed a predictive signature that 
discriminated those who did develop TB in the next period from those that remained free of disease for at 
least 2 years following sample collection(60, 61). Expression of interleukin (IL)-13 in the absence of AIRE 
(APECED, autoimmune regulator) was predictive for TB disease development within the next year in this 
high-risk population. Interestingly, when analysing individuals from the IL-13/AIRE group who progressed to 
TB in the following couple of months, there was also abundant expression of type I IFN-related genes, 
indicating detection of early disease markers in those individuals. Although this needs to be repeated in 
larger, longitudinal and independent cohorts, preferably also HIV-uninfected groups, it is an important 
proof of principle, illustrating the power of predictive TB biomarkers (table 1).  
3.5 Immune activation-based COR tests 
 T-cell activation-based CORs of TB have also been the subject of investigation. A recent study, performed in 
BCG-vaccinated infants who participated in the recent phase IIb efficacy trial of MVA85A(63), compared a 
number of immunological outcomes as potential correlates of risk at trial baseline and after administration 
of the MVA85A boosting vaccine versus placebo. 53 infants who developed active TB disease and 205 
controls who remained healthy were evaluated. An intriguing result was that infants who developed TB 
disease during follow-up had significantly higher levels of activated CD4+ T-cells, expressing D-related 
human leukocyte antigen at study baseline than infants who remained healthy(64, 65). Importantly, this 
result was validated independently in the cohort of M. tuberculosis-infected adolescents discussed earlier, 
in whom elevated CD4+ T-cell activation was also found to correlate with risk of TB(64). Elevated T-cell 
activation may thus reflect the same immunopathogenesis that underlies the observed upregulated IFN 
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response in TB progressors from the adolescent study (table 1). Taken together, the infant, adolescent and 
the GC6-74 household contact studies all imply that persons at risk of developing active TB have evidence 
of inflammation and/or immune activation. The source of this immune activation is not definitive and 
requires further study. In adolescents and household contacts, M. tuberculosis replication may be the 
primary driver of increased inflammation, but this cannot be the cause in the infants, who were all IGRA-
negative at sample collection. A notable result in the infant study was that T-cell responses to 
cytomegalovirus were significantly higher in infants who progressed to TB disease(64). This raises the 
hypothesis that underlying co-infections may drive immune activation(66, 67), which may be associated 
with risk of TB. Genetic predisposition to immune activation and other environmental factors may also be 
involved. Two other candidate COR of TB were identified in the 4–6-month-old infant cohort from the 
phase IIb MVA85A trial(63). Higher levels of Ag85A-binding immunoglobulin (Ig)G antibodies were observed 
in controls than in progressors. Ag85A-specific IgG was thus associated with reduced risk of developing TB 
disease(64). In addition, elevated frequencies of BCG-specific IFN-γ secreting T-cells, measured by ELISPOT 
assay at trial baseline, were also associated with reduced risk of developing TB disease. The latter result 
was surprising in light of the previous immune correlates study in BCG-vaccinated infants, which aimed to 
determine whether frequencies or cytokine co-expression patterns of BCG-specific CD4 or CD8 cells were 
associated with subsequent risk of TB disease(68). This study, which measured CD4+ and CD8+ T-cell 
expression of IFN-γ, TNF-α, IL-2 and IL-17 at 10 weeks of age, found no associations between frequencies or 
cytokine-expression patterns of BCG-specific CD4+ and CD8+ T-cells and subsequent risk of TB(68). Several 
other studies that also addressed T-cell activation status have shown that phenotypic markers of T-cell 
activation and/or differentiation can discriminate between distinct clinical presentations of TB infection. 
During antigen-driven differentiation T-lymphocytes pass through several stages (early, late and terminally 
differentiated effector cells), and each stage can be characterised by a set of cell surface markers. Since the 
differentiation process depends on antigenic stimulation, markers of T-cell differentiation may serve as 
indicators of M. tuberculosis replication or antigen load. T-cell expression of CD27 has been observed to 
show promise as a COR. CD27 is a member of the TNF receptor superfamily, which is constitutively 
expressed by the naive T-cells and early effector lymphocytes, but downregulated during late stages of 
effector cell differentiation. Therefore, late effector lymphocytes exhibit low to no CD27 expression(69–70). 
Several studies have demonstrated that significantly higher proportions of M. tuberculosis-specific IFN-γ-
producing CD4+ T-cells do not express CD27 (CD27−IFN-γ+ CD4+ ) in persons with active TB disease, 
compared with healthy controls. In addition, it has been shown that frequencies of CD27−IFN-γ+ CD4+ cells 
strongly correlated with the degree of pulmonary destruction(71) and TB treatment success(73, 76). 
Schuetz et al.(77) reported that HIV-infected patients without TB disease have higher proportions of 
CD27−IFN-γ+ CD4+ cells than HIV-negative persons without TB disease and suggested that accumulation of 
M. tuberculosis-specific CD27−CD4+ cells may reflect the degree of M. tuberculosis replication, thus 
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possibly identifying subclinical M. tuberculosis infection. The loss of CD27 expression on specific CD4+ T-
cells was shown to proceed the development of active TB disease in one HIV-infected patient who had 
recently HIV-seroconverted, lending further support to this hypothesis(77) (table 1). The accuracy of assays 
based on the modulation of CD27 may be increased by combining several tests either based on CD27 or on 
cytokine expression(78); however, further studies are needed to confirm better accuracy compared to 
IGRA. IFN-γ inducible protein-10 (IP-10) is a chemokine secreted by multiple cell types, including 
monocytes, endothelial cells and fibroblasts, in response to IFN-γ. It acts as a chemoattractant for 
monocytes/macrophages, T-cells, natural killer cells, and dendritic cells and promotes T-cell adhesion(79, 
80). IP-10 concentrations, measured after M. tuberculosis antigen exposure or in unstimulated blood, are 
elevated in patients with TB either with or without HIV co-infection either in blood(81–84) or urine(85, 86). 
High levels of plasma IP-10 was associated with incident TB in both HIV-uninfected(87) and HIV-infected 
subjects(88) (table 1). 
3.6 HBHA and other M. tuberculosis latency antigens  
Heparin-binding haemagglutinin (HBHA) antigen is expressed at the surface of a variety of mycobacterial 
species and promotes binding to host epithelial cells(89). This feature increases M. tuberculosis 
pathogenicity and facilitates the extrapulmonary dissemination of mycobacteria. Detection of T-cell 
responses specific to HBHA has been associated with LTBI, suggesting a protective role for the HBHA-
specific responses(90–93). This is supported by the presence of HBHA-specific CD8+ T-cells in LTBI and the 
proposed role of such cells in maintaining the latent state(94, 95). However, as previously stated, LTBI is 
considered a heterogeneous entity which may include spontaneous cure, stable and persistent 
asymptomatic infection and, as discussed earlier, early progression towards active disease(10). CORBIERE 
et al.(96) have suggested that measuring IFN-γ responses to two different mycobacterial antigens, ESAT-6 
and HBHA, may allow stratification of LTBI subjects into several groups. In this model, those who score 
negative to both antigens represent successful elimination of the M. tuberculosis infection, those who 
score positive to both antigens are in a stage of true latency able to control M. tuberculosis replication and 
those who are positive only to ESAT-6 have actively replicating M. tuberculosis (as in active TB disease). The 
latter is informed by the demonstration that ESAT-6 is produced at high levels during mycobacterial 
growth(97). Based on this model, the authors report that loss of the in vitro IFN-γ response to HBHA 
preceded development of TB in a dialysis patient(96). Other M. tuberculosis latency antigens have also 
been reported(98). Adaptation of M. tuberculosis to a state of non- or slow replicating persistence during 
LTBI, with downregulated metabolic activity and concomitant altered gene expression patterns have been 
suggested(99, 100). In this state, M. tuberculosis has been shown to induce the expression of the 48-gene-
encoding DosR regulon(101). T-cell responses to M. tuberculosis DosR-encoded latency antigens were 
particularly dominant in TST+ LTBI individuals, compared to successfully treated or active TB patients. T-cell 
47 
 
proliferation and IFN-γ production driven by these latency antigens was consistently seen in LTBI in many 
diverse genetic and geographic populations(102–104). Responses to one of these antigens, Rv2628, 
discriminated recent from remote LTBI in a cross-sectional study(104). Moreover, the ratio of responses 
between M. tuberculosis DosR-encoded antigens and ESAT6, in analogy with the results found for HBHA 
and ESAT6, correlated with low risk of TB disease(105). These results suggest that the evaluation of this 
response may be useful for identification of LTBI subjects who are more likely to develop active TB within 2 
years and may benefit from preventive treatment (QFT-IT-positive and Rv2628-negative) (table 1). In 
addition, it has been shown that the specific response to Rv2628 is found at the site of TB disease(106), 
emphasising the concept of TB as a spectrum of different stages of infection(10). 
3.7 Elevated proportion of peripheral monocytes as COR for identifying contacts of TB patients at highest 
risk of developing active TB  
SABIN and colleagues(107–109) showed in the 1920s that the ratio between monocyte and lymphocyte 
numbers in peripheral blood, or monocyte/lymphocyte (M/L) ratio, was associated with progressive 
outcome of mycobacterial infections in rabbits. Rediscovering this experimental study, a series of 
prospective cohort evaluations have recently been performed in adults, pregnant women and infants in 
sub-Saharan Africa(110–112). In each study an elevated M/L ratio was associated with risk of TB disease 
before the appearance of symptoms. The biological underpinning of this finding may be related to 
activation of myelopoiesis in the bone marrow induced by elevated expression of IFN-γ, which is involved in 
the antimycobacterial response, thus leading to increased myeloid cellularity in the blood(113, 114). Since 
lymphopoiesis is not activated in a similar manner, and peripheral lymphoid cells, including T- and B-cells, 
are recruited to the site of M. tuberculosis replication, this may lead to a decrease in peripheral blood 
lymphoid cells. The higher M/L ratio is thus likely to be a product of both these processes. Interestingly, in 
addition to this hypothesis, it was shown that in healthy donors a high M/L ratio was associated with 
antimycobacterial activity and with transcriptomic profiles characterised by an enrichment of IFN-
associated transcripts in monocytes. These data suggest that the M/L ratio may be associated with 
subclinical disease by acting as a marker of monocyte function(115) (table 1).  
 
3.8 Distinct host immune responses to BCG vaccination can obscure identification of COR  
Another TB COR study was recently completed in 10-week-old BCG-vaccinated infants from South Africa, 
who during 2 years of follow-up either progressed to TB disease (progressors) or remained healthy 
(controls) (116). Comprehensive comparisons of global gene expression and cellular responses to BCG 
between progressors and controls did not lead to identification of COR in these infants. However, gene 
expression profiles revealed two distinct clusters of infants, each of which contained both progressors and 
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controls. One cluster had enrichment of differentially expressed genes in biological pathways including IFN 
responses and T-cell activation, while the other cluster had enrichment of myeloid cell and glucose 
metabolism pathways. Importantly, within cluster 1 infants, those who progressed to TB had elevated 
monocyte to T-cell ratios and frequencies of BCG-specific CD4+ T-cells expressing IFN-γ, among other T-
helper type 1 cytokines. It was striking that the former finding is consistent with the M/L ratio associations 
with risk of TB (115, 116), while the latter is consistent with the observed immune activation and 
frequencies of IFN-γ-expressing Ag85B-specific T-cells identified as COR in the 4–6-month-old infant cohort 
from the phase IIb MVA85A trial. 
3.9 Conclusions 
 Although only a handful of studies have identified biomarkers of progression to TB, a picture is emerging 
from the common biological processes, including immune activation, IFN responses and changes in 
peripheral blood myeloid and lymphoid cells which have been clinically validated and are associated with 
risk of TB. Promising biomarkers and biomarker signatures are being discovered that may allow accurate 
prediction of progression from infection to active TB disease. Several of these biomarkers are being taken 
further towards test development, evaluation and possible use in clinical settings. However, despite this 
great progress, no biomarker signature has yet been identified that fully meets the performance goals for a 
prognostic test of progression from latent infection to TB disease set forward by the global health 
community led by the WHO and other stakeholders. Further intensified research efforts are required for 
ongoing biomarker discovery, evaluation and test development. In addition, it is critical that different 
markers and signatures are validated in different geographic settings (and thus different host genetic 
backgrounds and circulating pathogen lineages) to ensure that accuracy in different high-burden settings is 
sufficiently acceptable to enable a “screen and treat” strategy. Utility of such biomarkers is also highly 
dependent on translation of the test to a near-patient platform to allow testing in settings where patients 
at highest risk for progression present for care (e.g. HIV clinics in TB-endemic populations). Without further 
progress on the development of tests that better predict the development of active TB, we will not be able 
to eradicate the seedbeds of TB and achieve the end-TB strategy of the WHO.  
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CHAPTER 4: OBJECTIVES OF THE STUDY 
  
Mtb is able to establish a chronic asintomatically infection mainly in the lung and the balance between host 
immune response and the mycobacteria plays a fundamental role in the control of the Mtb replication 
(3,36). Although the immune response to Mtb has been deeply studied, as described in the previously 
chapters, the host factors that leads to the development to active TB disease are not fully understood. 
However, on the base of immunogical findings on Mtb infection, it is possible to speculate that the 
containment of the latent Mtb needs an acquired cellular response with specific characteristics of immune 
surveillance, differently contrasting the replicating Mtb requires effector and cytotoxic proprierty. 
Objective of the present study is to take a picture of the immunological status of patients with Mtb 
infection, characterizing their Mtb specific immune response, in order to find a correlation with  the 
different stages of Mtb infection.  
 
In the chapter 5 it is described the use of several cytometric approaches to evaluate the surface expression 
of the activation marker CD27 on Mtb-specific CD4+ T-cells, as a tool to diagnose active TB and LTBI.    
 
The chapter 6 is focused on flow cytometric characterization of the specific CD4 and CD8 T-cell responses to 
Mtb antigens contained within the QuantiFERON®-TB Gold Plus (QFT-Plus). QFT-Plus is the new generation 
of QuantiFERON-TB Gold In-Tube test (QFT-GIT) to identify the latent tuberculosis infection, it includes two 
tubes called TB1 and TB2 tubes which contain selected Mtb peptides designed to stimulate both CD4 and 
CD8 T-cells. Aim of the study was to analyze if the immune response to TB1 and TB2 stimulation could or 
not highlight differences between different TB stages.  
 
In the chapter 7, QFT-Plus performance was compared with that one of QFT-GIT in a cross sectional study 
of individuals with LTBI, active TB or treated for TB in the past. In this study, we wanted also to evaluate if 
the different ability to respond to TB1 and TB2 stimulation could associate or not with latency, TB disease 
or cured TB status. 
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CHAPTER 5: ASSESSMENT OF CD27 EXPRESSION AS A TOOL FOR ACTIVE AND LATENT TUBERCULOSIS 
DIAGNOSIS 
 
 
5.1 Abstract 
There are still no reliable tests to distinguish active tuberculosis (TB) from latent TB infection (LTBI). 
Assessment of CD27 modulation on CD4+ T-cells has been suggested as a tool to diagnose different TB 
stages. 
Objectives: To use several cytometric approaches to evaluate CD27 expression on Mycobacterium 
tuberculosis (Mtb)-specific CD4+ T-cells to differentiate TB stages. 
Methods: 55 HIV-uninfected subjects were enrolled: 13 active TB; 12 cured TB; 30 LTBI. Whole blood was 
stimulated with RD1-proteins or Cytomegalovirus-lysate (CMV). Interferon (IFN)-γ response was evaluated 
by cytometry. The proportion of CD27−/+ within the IFN-γ+ CD4+ T-cells or RATIO of the CD27-median 
fluorescence intensity (MFI) of CD4+ T-cells over the CD27 MFI of IFN-γ+ CD4+ T-cells was evaluated. 
Results: The greatest diagnostic accuracy in discriminating active TB vs. LTBI or cured TB was reached by 
evaluating the CD27+ CD45RA− cells within the IFN-γ+ CD4+ T-cell subset (76.92 sensitivity for both, and 
90% and 91.67% specificity, respectively), although the use of the CD27 MFI RATIO allows for stricter data 
analysis, independent of the operator. 
Conclusions: the study of CD27 expression using different approaches, whether it involves evaluation of 
CD45RA expression or not, is a robust biomarker for discriminating TB stages. 
 
5.2 Introduction 
The global tuberculosis (TB) epidemic is still not under control.1 Diagnosis of pulmonary active TB relies on 
the evaluation of clinical symptoms, radiological images and detection of Mycobacterium tuberculosis (Mtb) 
in patient respiratory samples, such as sputum. Microscopic detection of Mtb in sputum smears is the most 
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commonly used approach for diagnosing pulmonary TB and monitoring response to treatment 
(2,4).However, sputum smears have poor sensitivity, and a high proportion (20%–66%) of tuberculosis (TB) 
cases is smear-negative (2). Nucleic acid amplification–based tests are more sensitive for diagnosing ATB 
(2),but do not differentiate between live and dead Mtb, thus are not useful for monitoring treatment-
mediated clearance of Mtb. Although it takes a long time to obtain microbiological isolation and culture of 
Mtb from sputum, it remains the TB diagnostic gold standard (2). Blood-based host biomarkers for 
diagnosing TB are attractive alternatives to tests that rely on detecting mycobacteria. 
Interferon (IFN)-γ release assays (IGRAs) are new tools for latent TB infection (LTBI) diagnosis. These tests 
are based on the IFN-γ response to Mtb antigens as ESAT-6 and CFP-10 (3,4). They represent a 
breakthrough, however, they do not discriminate between active TB disease and LTBI (1,3-7). IGRA 
accuracy for LTBI diagnosis may be enhanced using other Mtb-specific antigens (8,9) or peptides selected 
from ESAT-6/CFP-10 (10-12), evaluating the response at the site of TB disease (13,14) or investigating host 
biomarkers other than IFN-γ in whole blood or peripheral blood mononuclear cells (PBMC) (10,14-21).  
Cytometry has been proposed as a potential tool to improve TB diagnosis by phenotypical and functional 
characterization of antigen-specific T-cells. The cytokine profile of Mtb-specific T-cells has been studied in 
depth with the aim of finding a correlation with TB status (20,22-29). However, existing data are currently 
inconclusive due to contrasting findings on the distribution of the various cytokine-producing CD4+ and 
CD8+ T-cell subsets. 
T-cell expression of surface molecules such as CD45RA, CD27 and CCR7 identifies different T-cell subsets 
that reflect different stages of cell differentiation (30-34). Interestingly, the effector T-cells are expanded 
during active Mtb replication, whereas the memory cells associate with control and eradication of Mtb 
infection (14,35-37). Moreover, several reports demonstrate that the decrease of CD27 surface expression 
on circulating Mtb-specific CD4 T-cells associates with the status of active TB disease (22,38-43).  
Studies in mice have demonstrated that the lack of CD27 expression on T lymphocytes identifies the 
functionally mature highly differentiated effector T-cells (44). In vivo studies show that in the lungs of Mtb-
infected mice, the effector CD4+ T-cells with a low CD27 expression differentiate from effector CD4+ T-cell 
precursors with a high CD27 expression (45). Moreover, it is shown that the Mtb infection leads to the 
accumulation of effector CD4+ T lymphocytes with low CD27 expression in the lungs, blood, and other 
organs (44,45). However no consequences on the clinical outcome have been observed in CD27 KO mice 
infected with Mtb (46).  
Interestingly, CD4+ T-cells with a low CD27 surface expression have also been described as a marker of lung 
tissue destruction during pulmonary TB, suggesting its use as an immune assay to monitor the efficacy of TB 
therapy (38). The studies on CD27 expression on Mtb-specific T-cells show similar and reproducible results, 
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despite the differences of the experimental settings and clinical characteristics of the enrolled patients 
(22,38-43,47). Therefore, the phenotype data of the CD4+ T-cells are more consistent compared to the 
cytokine profile studies, suggesting that CD27 evaluation on Mtb specific-CD4+ T-cells may be a useful tool 
for diagnosing TB stages. Recently, a new assay, the T-cell activation marker of TB (TAM-TB), has been 
proposed (39). Different from the other approaches, it evaluates the ratio of the median fluorescence 
intensity (MFI) of CD27 within the CD4+ T-cells over the MFI of CD27 in the Mtb-specific CD4 T-cells 
(39). The TAM-TB assay differentiates active TB from LTBI in children (39).  
In the present study, we used several concomitant approaches to evaluate whether detection of the CD27 
surface expression on Mtb specific-CD4+ T-cells is a useful marker to discriminate active disease from LTBI 
in adult individuals from a low TB-endemic country such as Italy. 
5.3 Materials and methods 
Study population and sample collection 
This study was approved by the Ethical Committee of the L. Spallanzani National Institute of Infectious 
Diseases (INMI), approval number 02/2007. Informed written consent was required to participate in the 
study that was conducted at INMI. 
Active TB was defined based on Mtb isolation from sputum culture. Mtb was drug-sensitive to the first line 
of TB drugs; patients were enrolled within 7 days of starting the specific treatment. Cured TB was defined 
as microbiological pulmonary TB after a 6-month course of treatment and when sputum resulted Mtb 
culture-negative upon the end of therapy. Cured TB patients were evaluated one year after therapy 
completion. LTBI was defined based on a positive score to QuantiFERON TB Gold In-Tube (QFT-IT) (Qiagen, 
Hilden, Germany) in the absence of clinical, microbiological and radiological signs of active TB. Within the 
LTBI group, remote or recent contacts with smear-positive pulmonary TB patients were reported. A portion 
of the recent contacts underwent prophylaxis. All these LTBI subjects were considered as a whole group 
because no significant differences were found in terms of the immune responses evaluated (data not 
shown). 
All enrolled subjects tested negative for HIV and none of the subjects enrolled had previously undergone 
treatment with immunosuppressive drugs. Demographic and epidemiological information were collected at 
enrollment (Table 1). 
Stimuli and antibodies 
Whole blood or peripheral blood mononuclear cells (PBMC) (in a small subgroup) were stimulated with 
recombinant proteins ESAT-6 and CFP-10 (Lionex, Braunschweig, Germany) (hereafter referred to as RD1 
proteins or RD1) at 4 ug/ml with a contamination of lipolisaccaride reported by the manufacturer of less 
than 0.05 IU/mg for ESAT-6 and equal to 66.7 IU/mg for CFP-10. RD1 proteins were used as a stimulus to 
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evaluate Mtb-specific response by intracellular staining assay (ICS), as previously described (22). 
Cytomegalovirus (CMV) lysate of the human CMV strain AD169 propagated in human foreskin fibroblast 
(Experteam, Venice, Italy) at 5 ug/ml and staphylococcal enterotoxin B (SEB) (Sigma, St Louis, MO, USA) at 
200 ng/ml were used as an uncorrelated antigen and positive control, respectively. Whole blood cells were 
co-stimulated with anti-CD28 and anti-CD49d monoclonal antibody (mAb) at 2 ug/ml each (BD Biosciences, 
San Jose, USA). Brefeldin A (BFA) (SERVA Electrophoresis GmbH, Heidelberg, Germany) was added at 
50 ug/ml to whole blood cells to prevent cytokine secretion. 
The following fluorescently conjugated mAb were used in this study: anti-CD8 Pacific Blue, anti-CD4 
peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated, anti-CD45RA phycoerythrin (PE)-Cy7-conjugated, 
anti-CD27 Horizon V500, anti–IFN-γ allophycocyanin (APC)-conjugated (all from BD Biosciences). 
Whole blood intracellular staining assay 
Heparinized peripheral blood was collected and 100 μl of whole blood were incubated with stimuli for 16 h 
at 37 °C within 2 h of blood collection. BFA was added after one hour of stimulation. Unstimulated whole 
blood cells served as a negative control of ICS. Whole blood cells were stained with mAb for surface 
markers and red cells were lysed with FACS Lysing Solution (BD Biosciences). Whole blood cells were 
permeabilized with PBS-1% BSA-0.5% saponin-0.1% NaN3 and stained with mAb for intracellular cytokines. 
At least 100,000 lymphocytes were acquired using a FACSCanto II flow cytometer (BD Biosciences). 
Flow cytometry data analysis 
Multiple-parameter flow cytometry data were analyzed using FlowJo (Tree Star Inc., San Carlos, CA) and 
SPICE software (provided by Dr. Roederer, Vaccine Research Center, NIAID, NIH, USA) (48). Cells were gated 
according to forward and side scatter plots and the frequency of single, double and triple cytokines 
producing CD4+ T-cells was evaluated using Boolean combination gates. Background cytokine production in 
the negative control of the ICS assay was subtracted from each stimulated condition. To score a positive 
CD4+ T-cell response we defined a detection limit of 0.03% of IFN-γ producing CD4+ T-cells, corresponding 
to at least 30 analyzed events. All donors were responsive to the SEB positive control in the ICS assay. The 
phenotypical analysis of RD1-response of CD4+ T-cells was evaluated by flow cytometry according to the 
expression of surface markers CD45RA and CD27 in the gate of IFN-γ+ CD4+ T-cells. The FACS results were 
generated by EP and blindly re-evaluated by a co-author, LP. The agreement of the results was high (k = 0.9) 
and the discrepancies were solved by discussion. 
Definition of the CD27 MFI RATIO 
For each sample, the ratio of the MFI of CD27 in the CD4+ T-cells over the MFI of CD27 in the CD4+ IFN-γ+ T-
cells was calculated as suggested by Portevin (39) (hereafter referred to as the CD27 MFI RATIO). 
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Statistical analysis 
Data were analyzed using SPSS software (Version 19 for Windows, Italy SRL, Bologna, Italy), and Stata 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). For continuous 
measures, medians and interquartile ranges (IQR) were calculated; the Kruskal–Wallis test was used for 
comparisons among several groups and the Mann–Whitney U test with Bonferroni correction for 
comparisons between more than 2 groups. The Fisher exact test was used for categorical variables. P values 
≤0.05 or ≤0.016 (if 3 groups were analyzed) after the Bonferroni correction were considered significant. 
A receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performances of the 
tests evaluated, and for scoring purpose we chose a cut-off point to maximize the sum of sensitivity and 
specificity(49,51). Test equality of ROC areas of the different cytometric approaches was performed to 
compare areas under the curves (AUC), using a test based on an algorithm suggested by DeLong et al., 
implemented by STATA software.52 
5.4 Results 
Characteristics of the patient population 
We enrolled 55 subjects, 13 active TB, 12 cured TB and 30 LTBI, selected to score positive to the QFT-IT to 
have better chances of obtaining a positive cytometric response after RD1-specific stimulation. The 
majority was male and BCG-unvaccinated and 50.9% were from Western Europe. Significant differences 
were found for origin (p < 0.0001) and BCG vaccination (p = 0.001) (Table 1). 
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Active TB associates with down modulation of CD27 expression 
CD4+ T-cells can be phenotypically divided into at least four different populations, based on the surface 
expression of CD45RA and CD27 (Fig. 1). Compared to active TB, a significantly higher proportion of 
CD45RA− CD27+ T-cells was associated with LTBI (p < 0.0001) and cured TB (p = 0.0005) (Fig. 1A). 
Conversely, active TB was characterized by a significantly higher proportion of CD45RA− CD27− T-cells 
compared to LTBI and cured TB (p = 0.0003 and p = 0.005 respectively) (Fig. 1B). The pie charts represent 
the proportion of CD45RA+/−and CD27+/− in the different groups (Fig. 1C). 
 
 
Figure 1 A CD45RA
−
CD27
+
phenotype significantly associates with LTBI, whereas active TB associates with a 
CD45RA
−
CD27
−
phenotype within the IFN-γ
+
CD4
+
T-cells. Whole blood was stimulated overnight with RD1 recombinant 
proteins (ESAT-6 and CFP-10) and the phenotype of CD4
+
IFN-γ
+
 T-cells was evaluated by flow cytometry according to 
the surface expression of CD27 and CD45RA
−
. Analysis of CD45RA
−
 CD27
+
 IFN-γ
+
 CD4
+
 T-cells among groups (A). 
Analysis of CD45RA
−
CD27
−
 IFN-γ
+
 CD4
+
 T-cells among groups (B). The horizontal lines represent the median; statistical 
analysis was performed using the Mann–Whitney test with Bonferroni correction and p value was considered 
significant if < 0.016 (A–B). Pie charts represent the proportion of CD45RA
+/−
 CD27
+/−
 CD4
+
IFN-γ
+
 T-cells in the different 
groups in response to overnight stimulation with RD1 recombinant proteins (C). Footnotes: TB: tuberculosis, LTBI: 
latent TB infection, IFN: interferon. 
 
RD1-specific T-cell response may also be analyzed evaluating only the CD27+/− within the IFNγ+ CD4+ T-
cells. Compared to active TB, we showed a higher frequency of CD4+ IFNγ+CD27+ T-cells in LTBI 
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(p < 0.0001) and cured TB (p = 0.001) (Fig. 2A) indicating that increased CD27 expression is a marker of Mtb 
containment. Conversely, CD4+ IFN-γ+CD27− T-cells associated with active TB in comparison with LTBI 
(p < 0.0001) and cured TB (p = 0.001) (Fig. 2B), indicating that loss of CD27 expression is a marker of Mtb 
uncontrolled replication. 
 
 
 
Figure 2 LTBI significantly associates with a CD27
+
phenotype, whereas active TB associates with a CD27
−
phenotype 
within the IFN-γ
+
CD4
+
T-cells. Whole blood was stimulated overnight with RD1 recombinant proteins (ESAT-6 and CFP-
10) and the phenotype of IFN-γ
+
 CD4
+
 T-cells was evaluated by flow cytometry according to the surface expression of 
CD27. Analysis of CD27
+
 IFN-γ
+
 CD4
+
 T-cells among groups (A). Analysis of CD27
−
 IFN-γ
+
 CD4
+
 T-cells among groups (B). 
The horizontal lines represent the median; statistical analysis was performed using the Mann–Whitney test with 
Bonferroni correction and p value was considered significant if < 0.016 (A–B). Footnotes: TB: tuberculosis, LTBI: latent 
TB infection, IFN: interferon. 
A higher CD27 MFI RATIO associates with TB disease: 
Since modulation of the surface expression of CD27 allows for discriminating TB stages, we analyzed the 
data using an additional cytometric approach based on the MFI evaluation of CD27 in the CD4+ T-cells. This 
methodology permits the operator to work without having the responsibility (or bias) to select the 
CD27+/− gate, therefore leading to a more accurate and stringent analysis. The data were analyzed 
evaluating the ratio of the MFI of CD27 in the CD4+ T-cells over the MFI of CD27 in the CD4+ IFN-γ+ T-cells, 
as suggested by Portevin (39). 
In a subgroup of subjects, the evaluation of the CD27 MFI RATIO was concomitantly conducted in PBMC 
and whole blood, and the analysis showed a higher CD27 MFI RATIO in active TB compared to LTBI, 
independent of the biological sample used (data not shown). Consequently, to simplify and facilitate the 
experimental procedure, the study was further conducted in whole blood samples (Fig. 3). We found a 
higher CD27 MFI RATIO in active TB compared to the cured TB (p = 0.03) and to LTBI (p = 0.0005) which was 
highly significant (Fig. 3A). 
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To evaluate the specificity of the result obtained, we analyzed the CD27 MFI RATIO in response to the 
uncorrelated CMV antigen. No significant differences were found among the groups analyzed (Fig. 3B). 
Therefore, a higher CD27 MFI RATIO in response to the RD1 antigen stimulation is a consequence of a lower 
CD27 expression only after Mtb-specific stimulation. 
 
 
Figure 3 A higher CD27 MFI RATIO significantly associates with active TB disease. Whole blood was stimulated 
overnight with RD1 recombinant proteins (ESAT-6 and CFP-10) and the phenotype of IFN-γ
+
 CD4
+
 T-cells was evaluated 
by flow cytometry according to the surface expression of CD27. The CD27 MFI RATIO is represented by the MFI of 
CD27 in the CD4
+
 T-cells over the MFI of CD27 in the IFN-γ
+
 CD4
+
 T-cells. The CD27 MFI RATIO referred to Mtb-specific 
T-cell response (A). The CD27 ratio referred to CMV-specific T-cell response (B). The horizontal lines represent the 
median; statistical analysis was performed using the Mann–Whitney test with Bonferroni correction and p value was 
considered significant if <0.016 (A–B). Footnotes: TB: tuberculosis, LTBI: latent TB infection, IFN: interferon, CMV: 
Cytomegalovirus, MFI: median fluorescence intensity. 
Accuracy of the different cytometric approaches to evaluate CD27 expression 
Considering the significant differences found on the modulation of the CD27 in Mtb-specific CD4+ T-cells 
with the different cytometric approaches used, we performed the ROC analysis for scoring purposes 
(Table 2). AUC analysis showed significant results with good diagnostic accuracy for TB diagnosis (Table 2). 
Interestingly, the evaluation of the CD27+CD45RA−IFN-γ+CD4+ T-cells led to the highest accuracy for the 
discrimination of active TB from LTBI or cured TB with a sensitivity of 76.92% for both and specificity of 
90.00% and 91.67 respectively (Table 2). The method based on the CD27 MFI RATIO showed a higher 
specificity to distinguish active TB from LTBI, probably due to the use of MFI which reduces the risk of any 
possible bias in the data analysis (Table 2). 
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We also assessed if there were differences among the AUC obtained from the different tests evaluated. No 
significant differences were found comparing the AUC, either for discriminating active TB from LTBI 
(p = 0.512) or active TB from cured TB (p = 0.536). 
 
 
 
5.5 Discussion 
In this study, among the IGRA-responders, we show that: (i) active TB significantly associates with an 
increase of the CD27− subset of Mtb-specific CD4 T-cells in whole blood; (ii) this result is Mtb-specific, as 
shown by the absence of CD27 modulation among the groups studied after in vitro CMV stimulation; (iii) 
the most accurate results for TB diagnosis are reached by evaluating the CD27 surface expression in the 
CD4+ IFN-γ+ T-cell subset (within the total IFN-γ+ or IFN-γ+ CD45RA− T-cells), although the use of the CD27 
MFI RATIO may allow for a stricter data analysis, independent of the operator. In conclusion, we show that 
the modulation of the CD27 expression is a robust biomarker for TB diagnosis, as shown by the use of 
different cytometric approaches. 
We found that the evaluation of the CD27+ CD45RA− IFN-γ+ CD4+ T-cells subset has a greater diagnostic 
accuracy for discriminating active TB from LTBI or cured TB, compared to the other cytometric approaches 
employed here to evaluate CD27 modulation, with a sensitivity for active TB diagnosis of 76.92% for both 
and a specificity of 90.00% and 91.67% respectively. This method is based on the gate selection of 
CD27+/− T-cells by the operator, therefore, the choice of the negative or positive CD27 cell population may 
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constitute a bias of the test. Differently, the CD27 MFI RATIO approach allows for overcoming this potential 
problem because it analyzes the MFI of CD27 on the CD4+ IFN-γ+ T-cell population directly. Moreover, the 
calculation of the ratio allows for normalization of the results, avoiding possible discrepancies in the MFI of 
CD27 in the CD4+ IFN-γ+ T-cell subset due to the influence of the total surface expression of CD27 on CD4+ T-
cells. Furthermore, here we confirm the results reported in a high TB-endemic country as Tanzania (39) in a 
low TB-endemic country as Italy (1), demonstrating that it is possible to reproduce the experimental setting 
using whole blood instead of PBMC (39), allowing for easier manipulation of the samples for routine use. 
CD27 is a member of the TNF-receptor superfamily (53). Therefore, the decrease of CD27 expression on 
CD4+ T-cells indicates the presence of highly differentiated effector T-cells that are able to produce 
cytokines (38,44,45,54). TB is a chronic disease that leads to the increase of terminally differentiated T-cells 
(14,22,43,55). In the present study, we show that one year after completion of TB therapy the level of CD27 
expression increases in cured TB patients, indicating that the lack of a sustained inflammation leads the T-
cells toward a less differentiated phenotype, probably with memory features. Our data are supported by 
the finding that 2 months of TB therapy are enough to observe a lower proportion of CD27lowCD4+ IFN-γ+ T-
cells (38). This evidence suggests that CD27 may also be a useful tool for monitoring TB therapy efficacy. 
Potential limitations of the present study should be considered. First, the study was performed among the 
IGRA-responders, not considering that the IGRA-negative subjects among the active TB cases can be 
between 10 and 15% (6). However, this is a limitation of all the immune-experimental approaches tested in 
the literature (20,56) that indeed need to be overcome. Then, we performed a cross-sectional study, 
analyzing a relatively small number of subjects within each group. Although a larger patient population is 
needed to validate our findings, the evaluation of the surface CD27 expression on T-specific cells may have 
the required characteristics to exploit it as a TB biomarker for routine use. In addition, considering the total 
population analyzed, the sensitivity of the assay for active TB detection needs to be increased. This can 
probably be achieved by modifying the type of antigen (other than RD1), its composition (peptides instead 
of proteins) and incubation time (increasing from 16 h to 24 h). Finally, the decision to use a cytometric 
approach may generate doubts about the consistency of the assays for routine use due to reproducibility 
issues (dependent on the characteristics of the lasers, the type of instrument employed, the antibodies 
which may have been produced from different clones or labeled with different fluorochromes, or 
inconsistency due to the lack of quality controls) and the need to generate standard operating protocols 
(57,58). However, in this study using the CD27 MFI RATIO, we obtained an accuracy for TB diagnosis similar 
to that reported by Portevin who described a slightly higher sensitivity and lower specificity, probably due 
to the use of two antigen stimulations [purified protein derivative (PPD) and RD1] (39) instead of only one 
used in the present study. 
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In summary, the evaluation of the surface CD27 expression on T-specific cells may have the required 
characteristics to exploit it as a TB biomarker for routine use, although for the moment, this is only feasible 
in the IGRA-responders. Larger patient populations are needed to validate these findings. 
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CHAPTER 6: FIRST CHARACTERIZATION OF THE CD4 AND CD8 T-CELL RESPONSES TO QUANTIFERON-TB 
PLUS 
 
 
 
6.1 Abstract 
Introduction 
QuantiFERON®-TB Gold Plus (QFT-Plus) is the new generation of QuantiFERON-TB Gold In-Tube test to 
identify latent tuberculosis infection (LTBI). QFT-Plus includes TB1 and TB2 tubes which contain 
selected Mycobacterium tuberculosis (Mtb) peptides designed to stimulate both CD4 and CD8 T-cells. Aim 
of this study is the flow cytometric characterization of the specific CD4 and CD8 T-cell responses to Mtb 
antigens contained within QFT-Plus. 
Methods 
We enrolled 27 active tuberculosis (TB) patients and 30 LTBI individuals. Following stimulation with TB1 and 
TB2, antigen-specific T-cells were characterized by flow cytometry. Data were also correlated with the 
grade of TB severity. 
Results 
TB1 mainly elicited a CD4 T-cell response while TB2 induced both CD4 and CD8 responses. Moreover, the 
TB2-specific CD4 response was detected for both active TB and LTBI patients, whereas the TB2-specific CD8 
response was primarily associated with active TB (p = 0.01). 
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Conclusions 
To our knowledge, we report the first characterization of the CD4 and CD8 T-cell response to QFT-Plus. CD8 
T-cell response is mainly due to TB2 stimulation which is largely associated to active TB. These results 
provide a better knowledge on the use of this assay. 
6.2 Introduction 
Tuberculosis (TB), being responsible for 9.6 million cases and 1.5 million deaths annually, represents a 
major public health problem (1).Moreover, latent TB infection (LTBI), which is estimated to affect one-third 
of the world's population, may progress to active disease in about 3–15% of the LTBI individuals during 
their lifetimes (2,3). Considering that LTBI subjects are the seedbed of TB disease, diagnosing and treating 
LTBI is one of the main goals to control the TB epidemic (4-7). Tuberculin skin test (TST) and T-cell 
interferon-γ release assays (IGRAs) are the routine diagnostic tools to identify LTBI. Two IGRAs are 
commercially available: the QuantiFERON®-TB Gold In-Tube (QFT-GIT) (Qiagen, Hilden, Germany) and the T-
SPOT.TB (Oxford Immunotec, Abingdon, UK). IGRAs have several advantages: the results are not affected by 
Bacille Calmette–Guérin (BCG)-vaccination(4-7) and by the majority of environmental mycobacteria; 
moreover, only one patient-visit is required. However, since these assays are based on an immune 
response detection, they have a poor sensitivity in children and in immune-compromised subjects (7-9) 
furthermore, they do not discriminate between active TB and LTBI (5) and poorly correlate with the risk of 
developing active disease (3,10,11).  
In the last few years several studies have described the role of CD8 T-cell responses in TB. Mtb-specific CD8 
T cells have been associated with active TB, both in HIV-uninfected and infected patients (12-15). And to 
recent infections, in adults and young children recently exposed to a smear-positive active TB case 
(16,17). An increase of the CD8 T-cell responses associates with Mtb load, as found for both humans and 
animal models (12,18-20). Importantly, longitudinal studies have shown a decrease of the CD8 T-cell 
response during anti-TB treatment (12,13,21).  
Interestingly, a study on QFT-GIT performance has shown that the addition of peptides for eliciting CD8 T-
cell responses to QFT-GIT tubes increases the sensitivity of the test for LTBI detection (22). On the base of 
this evidence, recently QuantiFERON®-TB Gold Plus (QFT-Plus) (23-28), has been proposed as a new 
generation of QFT-GIT. QFT-Plus includes two tubes, called TB1 and TB2 respectively, with Mycobacterium 
tuberculosis (Mtb) antigens to elicit a specific immune response. The TB1 tube, contains peptides derived 
from ESAT-6 and CFP-10 (TB-7.7, present in QFT-GIT, has been removed), and it is designed to induce a 
specific CD4 T cells response. TB2 contains newly designed peptides stimulating interferon (IFN)-γ 
production by both CD4 and CD8 T cells (29). However, as previously described, due to the lack of a gold 
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standard for LTBI detection, active TB cases are used as surrogate reference standard for evaluating test 
accuracy (5).  
At present, the specific response to QFT-Plus TB1 and TB2 tubes has not been characterized. Therefore, the 
main aim of this study is to evaluate by flow cytometry the specific CD4 and CD8 T-cell responses to the 
Mtb antigens contained within the QFT-Plus test in patients with active TB and LTBI. 
6.3 Materials and methods 
Population characteristics 
This study was approved by the Ethical Committee of “L. Spallanzani” National Institute of Infectious 
Diseases (INMI), approval number 72/2015. Written informed consent was required to participate in the 
study that was conducted at INMI. We prospectively enrolled HIV-uninfected patients with pulmonary 
active TB and LTBI. Active TB microbiologically diagnosed was defined based on the Mtb isolation from 
sputum culture. Active TB clinically diagnosed was defined based on the clinical and radiological lung 
lesions associated with TB in the absence of Mtb isolated in the sputum that completely recovered after TB-
specific treatment for 6 months. Microbiological TB was characterized by first line Mtb drug-sensitive 
isolates. Patients were enrolled within 7 days of starting the specific treatment. 
In the absence of clinical, microbiological and radiological signs of active TB, LTBI was defined based on a 
positive score to QFT-GIT (Qiagen, Hilden, Germany). The LTBI group included subjects with a remote 
infection (reported contact with a smear-positive pulmonary TB patient at least 3 years before the 
enrollment) and subjects reporting a recent contact (no more than 3 months), LTBI subjects reporting the 
time of exposure between “more than 3 months” and “3 years” were not enrolled (30,31). None of the 
subjects enrolled had previously undergone treatment with immunosuppressive drugs. Demographic and 
epidemiological information were collected at enrollment and are reported in Table 1. 
Chest X-ray evaluation 
All chest X-rays (rendered anonymous) were evaluated for the presence of nodules, fibrosis, infiltrates, 
cavitation, bronchial spread, miliarity, pleural effusion and adenopathy, as previously reported (32). Cavity 
size in centimeters was recorded (<4 cm, ≥4 cm). The proportion of the affected lung was analyzed by a 
visual estimate of the extent of parenchymal infiltrates; a proportion of 30% of affected lung was used as 
our internal cut-off value to grade TB severity. In agreement with literature data (33) and on the basis of 
experience, the disease was graded (by DG, FP, RU) using a sliding scale of severity as follows: 0: normal 
chest X-rays; 1: mild grade (nodules and or infiltrates with proportion of lung affected <30%); 2: 
intermediate grade (infiltrates with proportion of lung affected >30% and/or cavitation <4 cm in diameter); 
3: high grade (an infiltrate of any percentage of extension with cavitation >4 cm in diameter and/or 
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bronchial spread and/or miliarity and/or pleural effusion and/or adenopathy). All subjects underwent 
standard chest X-rays at the time of TB diagnosis. 
QFT-GIT and QFT-Plus 
QFT-GIT and QFT-Plus assay was performed for each patient. QFT-Plus kits were donated by Qiagen and 
used according to manufacturer's instructions (29).  
Levels of IFN-γ were quantified by ELISA and the QFT-Plus Analysis Software (available 
from www.quantiFERON.com) was used to analyze raw data and to calculate the results in international 
units per milliliter (IU/ml). The software performs a quality control assessment of the assay, generates a 
standard curve and provides a test result for each subject. Test results were interpreted according to 
manufacturer's criteria (29).  
Intracellular staining assay 
Intracellular staining (ICS) was performed, concomitantly to QFT Plus, for each patient. Peripheral blood 
mononuclear cells (PBMC) were isolated using Ficoll density gradient centrifugation and resuspended in 
complete RPMI-16-40 medium (Gibco, CA, USA) with 10% fetal bovine serum (PAA Laboratories GmbH, 
Pasching, Austria). To characterize by flow cytometry the Mtb-specific T-cell response, 1 × 106 PBMC 
resuspended in 1 ml of medium, were dispensed in TB1, TB2, Mitogen and Nil tubes of QFT-Plus kit. After a 
1-h incubation, PBMC were transferred in polystyrene round-bottom tubes, 1 μl/ml of Golgi plug (BD 
Biosciences San Josè , USA) was added to inhibit cytokine secretion and anti-CD28 and anti-CD49d 
monoclonal antibodies (mAb) at 2 μg/ml each, were added to co-stimulate cells. 
Following an incubation of 16–24 h, the ICS was performed. As previously described (14,34-36), PBMC were 
stained with anti-CD4 peridinin chlorophylprotein (PerCp)-Cy5.5 conjugate, anti-CD8 allophycocyanin (APC)-
H7 conjugate, anti-CD3 Horizon V500 conjugate and anti-IFN-γ Pacific Blue (PB) conjugate (all from BD 
Bioscences). The Mtb-specific T-cell response was characterized evaluating the frequencies of IFN-γ CD4 
and IFN-γ CD8 T cells (Fig. 1). At least 200,000 lymphocytes were acquired with a FACS CANTO II (BD, 
Bioscences). Cytometry data were analyzed using FloJo software. Background cytokine production in the Nil 
tube was subtracted from each stimulated condition. If the background was higher than half of the antigen-
specific response, the results were scored as negative. A frequency of IFN-γ-producing T cells of at least 
0.03% was considered as positive response. 
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Figure 1. Representative dot plots of the TB2-induced T-cell response of an active TB patient. PBMC were stimulated 
overnight with TB1 and TB2 antigens and analyzed by flow cytometry for the intracellular production of IFN-γ. The 
frequency of Mtb-specific T cells was calculated from the proportions of CD4 IFN-γ T cells and CD8 IFN-γ T cells. 
 
Statistical analysis 
Data were analyzed using SPSS software (Version 19 FOR Windows, Italy SRL, Bologna, Italy). The median 
and interquartile ranges (IQRs) were calculated for continuous measures. The Chi-Square test was used for 
proportions. The Kruskal–Wallis test was used for comparison among several groups and the Mann–
Whitney U test was used for pairwise comparison. The Spearman rank correlation was used to correlate 
continuous variables; rs ≥ 0.7 was considered a high correlation, 0.7 < rs > 0.5 was considered a moderate 
correlation and rs ≤ 0.5 was considered a low correlation. The Fisher exact test was used for categorical 
variables. 
6.4 Results 
Features of the population 
A total of 57 participants were enrolled: 27 with active pulmonary TB (23 microbiologically diagnosed and 4 
clinically diagnosed) and 30 with LTBI (18 remote LTBI and 12 recent LTBI). Fifty-five percent of the enrolled 
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subjects were from Western Europe; no significant differences were found for sex, age, origin and BCG 
vaccination among the different groups (Table 1). 
 
 
Table 1: Demographic characteristics of enrolled patients 
 ACTIVE TB REMOTE LTBI RECENT LTBI TOTAL 
N (%) 27 (47) 18 (32) 12 (21) 57 (100) 
Age Median (IQR) 38 (28-44) 41 (35.7-60.7) 47 (28.5-60.5) 40 (32-51) 
Sex     
Female N (%) 13 (48) 11 (61) 8 (67) 32 (56) 
Origin      
West Europe (%) 10 (37) 11 (61) 9 (75) 30 (53) 
East Europe (%) 10 (37) 6 (33) 2 (17) 18 (31) 
Asia (%)  4 (15) 0 (0)  0 (0) 4 (7) 
Africa (%) 2 (7) 1 (6)  1 (8) 4 (7) 
South America 1 (4)    
BCG      
Vaccinated (%) 17 (63) 7 (39) 3 (25) 27 (47) 
Footnotes: TB: tuberculosis; LTBI: latent tuberculosis infection; BCG: bacillus Calmette-Guérin , IQR: 
interquartile range 
 
 
QFT-Plus evaluation among active TB and LTBI subjects 
QFT-GIT and QFT-Plus assay were performed for each patient (Fig. 2 and Table 2). To evaluate the 
sensitivity of the test we used as a surrogate for Mtb infection, the data generated on active TB patients. 
Therefore the sensibility of the tests for Mtb infection in the active TB group was similar: 89% for QFT-GIT 
and 85% for QFT-Plus. Among the active TB patients, the proportion of TB1-responders was 78% whereas 
for TB2 it was 85% (Table 2). For LTBI subjects, the proportion of QFT-Plus responders to TB1 and TB2 was 
100%, both for recent and remote infection (Table 2). No significant differences were found comparing the 
IFN-γ production to TB1 or TB2 among groups (Fig. 2). All samples scored positive to the mitogen 
stimulation. 
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Figure 2. Evaluation of IFN-γ production using QFT-Plus kit. The IFN-γ T-cell response was evaluated in active TB 
patients and in LTBI subjects with recent and remote infection, one day after whole blood incubation in TB1 and TB2 
tubes of the QFT-Plus kit. Horizontal lines indicate the median. The dotted line represents the cut-off value of 
0.35 IU/ml. TB: tuberculosis, LTBI: latent tuberculosis infection; IU: international unit; IFN: interferon; QFT: 
QuantiFERON. 
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Table 2: Mtb specific response to TB1 and TB2 stimulation in the different groups 
  
 
N  (%) of responders 
 
  
Antigen response to 
ACTIVE TB 
 27 (47) 
REMOTE LTBI  
18 (32) 
RECENT LTBI  
12 (21) 
TOTAL  
57 (100) 
QFT-GIT  TB antigen 24 (89) 18 (100) 12 (100) 54 (95) 
QFT-PLUS 
 TB1 21 (78) 18 (100) 12 (100) 51 (89) 
TB2 23 (85) 18 (100) 12 (100) 53 (93) 
Concomitant TB1 and TB2 21 (78) 18 (100) 12 (100) 51 (89) 
TB1 only 0 (0) 0 (0) 0 (0) 0 (0) 
TB2 only 2 (7) 0 (0) 0 (0) 2 (4) 
TB1 or TB2 23 (85) 18 (100) 12 (100) 53 (93) 
ICS 
CD4 
TB1 22 (81) 17 (94) 12 (100) 51 (89) 
TB2 24 (89) 15 (83) 11 (92) 50 (88) 
Concomitant TB1 and TB2 22 (82) 15 (83) 11 (92) 48 (84) 
TB1 only 0 (0) 2 (11) 1 (8) 3(5) 
TB2 only 2 (7) 0 (0) 0 (0) 2(4) 
CD8 
TB1 4 (15) 3(18) 4 (33) 11 (19) 
TB2 12 (44) 3 (18) 3 (25) 18 (32) 
Concomitant TB1 and TB2 4 (15) 3 (18) 3 (25) 10(18) 
TB1 only 0 (0) 0 (0) 1 (8) 1(2) 
TB2 only 8 (30) 0 (0) 0 (0) 8(14) 
Footnotes: Mtb: Mycobacterium tuberculosis; QFT: QuantiFERON; TB: tuberculosis; LTBI: latent tuberculosis infection; 
ICS: intracellular staining N:number 
 
 
Characterization of the CD4 and CD8 T-cell responses: evaluation of the proportion of responders to QFT-
Plus by flow cytometry 
Our first goal was to compare the CD4 and CD8 T-cell responses elicited by the same antigen stimulation 
(Fig. 3). To assess the specificity of the ICS assay, 10 healthy donors not exposed to Mtb and scored 
negative to QFT-Plus, were enrolled. We found that the specificity of the ICS assay to detect a TB infection 
(latent or active TB status) was 100% (data not shown). 
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Among those with active disease, TB1 induced a CD4-specific T-cell response in 81% of subjects and a CD8-
specific response in only 15% of them. On the other hand, TB2 induced a CD4-specific T-cell response in 
89% of subjects and a CD8-specific response in 44% of those (Fig. 3, Table 2). 
Among the remote LTBI subjects, TB1 induced a CD4-specific T-cell response in 94% and a CD8-specific T 
cell response in only 18% of them (Table 2). The TB2 induced a CD4-specific T-cell response in 83% of the 
sample evaluated and a CD8-specific T cell response in 18% of them (Table 2). 
Lastly, for the recent LTBI subjects, TB1 induced a CD4-specific T-cell response in 100% and a CD8 T-cell 
response in 33%. After TB2 stimulation we found a CD4-specific T-cell response in 92% and a CD8 T-cell 
response in 25% for both, CD4 and CD8 T-cell subsets (Table 2). Interestingly a selected CD8 response to 
TB2 stimulation and not to TB1 was found only in patients with active TB (8 of them) (Table 2). 
These data indicate that TB1 stimulation induces mainly a CD4 T-cell response in all studied groups, while 
TB2 stimulation elicits a CD4 response in all groups and a selective CD8 T-cell response in subjects with 
active Mtb replication, either with active disease or with a recent Mtb exposure. 
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Figure 3. TB2 stimulation induces a CD8 T-cell response in active TB patients. Flow cytometric evaluation of CD4 (A) 
and CD8 (B) T-cell to TB1 and TB2 antigens in active TB patients and LTBI subjects with recent and remote infection. 
The response was scored positive if the frequency of IFN-γ producing T cells was at least 0.03%. The horizontal lines 
represent the medians. Statistical analysis was performed using the Mann–Whitney U test and the p value was 
considered significant if ≤0.05. TB: tuberculosis, LTBI: latent tuberculosis infection. 
Evaluation of CD4 and CD8 T-cell frequencies to TB1 and TB2 by flow cytometry 
To better characterize the CD8-specific T cells, we evaluated the frequency of the responses to TB1 and 
TB2. Among active TB patients, the CD8 response to TB2 was significantly higher than that one generated 
by TB1 (p = 0.01; Fig. 3B). Moreover, the active TB group has a frequency of CD8 response to TB2 
stimulation significantly higher compared to that one elicited in the remote LTBI subjects (p = 0.04). These 
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data demonstrate that the Mtb-specific CD8 T-cell response associates with TB2 stimulation in active TB 
patients. 
Then we compared the frequency of antigen-specific CD4 and CD8 T cells in response to the same 
stimulation. In LTBI subjects, a significantly higher frequency of the CD4 response to TB1 (p < 0.0001) and 
TB2 (p = 0.0005) was found in comparison to that one generated by CD8 T cells (Table 3). These data 
indicate that TB2 stimulation seldom induces a CD8 response in remote LTBI subjects. 
Active TB patients showed a significantly higher frequency (p < 0.0001) of TB1-induced CD4 T cells 
compared to the levels found for the CD8 T cells. Since TB2 stimulation induced both a CD4 and a CD8 T-cell 
response we did not find significant differences comparing the frequency of the two antigen specific T-cell 
subsets. Interestingly, in active TB patients we found a positive and significant correlation between the 
frequencies of CD4 T cells and that one of the CD8 T cells in response to TB2 stimulation (rs = 0.76, 
p < 0.0001). These results highlight the capacity of the cells from active TB patients to respond with both 
CD4 and CD8 T-cell subsets to TB2 stimulation. 
Table 3: Comparison of the frequencies of the CD4 and CD8 T-cell response to TB1 and TB2 in the 
different groups 
 Frequency of the CD4 vs CD8 T-cell response 
 TB1  TB2 
 
ACTIVE 
TB 
p* 
REMOTE 
LTBI 
p* 
RECENT 
LTBI 
p* 
 
ACTIVE 
TB 
p* 
REMOTE 
LTBI 
p* 
RECENT 
LTBI 
p* 
ACTIVE TB 
 
<0.0001 - -  
0.1 
 
- - 
REMOTE 
LTBI 
 
- <0.0001 -  - 
0.0005 
 
- 
RECENT  
LTBI 
 
- - 0.02  - - 
0.02 
 
Footnotes: Mtb: Mycobacterium tuberculosis; TB: tuberculosis; LTBI: latent tuberculosis infection;  
p*= significance according the Mann-Whitney  test. 
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Impact of the severity of TB disease and mycobacterial load on QFT-Plus results 
Finally, we evaluated whether the severity of TB disease may influence the response to QFT-Plus. Among 
the parameters used to estimate the clinical severity we used the evaluation of the lung lesions based on 
the radiology findings. To better analyze the results, the data from patients with intermediate/high severity 
(grades 2 and 3) were combined and compared to those from patients with low severity (grade 1). As 
shown in Table 4 the patients with intermediate/high severity TB had a similar proportion of responders 
(84%) to QFT-Plus assay compared to patients with low TB severity (88%). Analyzing the specific immune 
results, CD8 T-cell response to TB2 was found in 53% (10 out 19) of patients with intermediate/high 
severity TB and only in 25% (2 out 8) of the low severity TB group (Table 4, Fig. 4). Moreover stratifying the 
active TB patients according to the microbiological diagnosis, we found that the TB2-induced CD8 response 
was associated with a microbiological diagnosis of TB more than to a clinical TB diagnosis (48% vs 25%) 
(Table 4). To note that among the active TB, the CD8 responders either classified as severe TB (8/10) or by a 
microbiological diagnosis (8/11), a selective TB2 response was observed (Table 4). These results suggest 
that CD8 T cell response associate with the radiological severity of TB disease and with the mycobacterial 
load. 
 
 
Figure 4. Impact of TB disease severity on CD4 and CD8 T-cell responses. Flow cytometric evaluation of CD4 and CD8 
responses to TB1 and TB2 antigens in active TB patients. Patients were stratified according the grade of TB severity: 
low and intermediate/high severity. The bars represent the number of patients responding to TB1 and TB2 
stimulation. TB: tuberculosis. 
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Table 4: Response to TB1 and TB2 stimulation according to the severity of active TB and the positivity of the 
mycobateria culture 
 ACTIVE TB 
N (%) of responders 
   Radiological Classification Microbiological Classification 
  
Antigen 
response to 
Low severity 
TB 
8 (30) 
Intermediate 
High severity TB 
19 (70) 
Microbiological 
confirmed TB 
23 (85) 
Clinical 
TB 
4 (15) 
QFT-GIT  TB antigen 8 (100) 16 (84) 20 (87) 4 (100) 
QFT-
PLUS 
 TB1 7 (88) 14(74) 18 (78) 3 (75) 
TB2 7 (88) 16(84) 20 (87) 3 (75) 
Concomitant TB1 and 
TB2 
7 (88) 14 (74) 18 (78) 3 (75) 
TB1 only 0 (0) 0(0) 0 (0) 0 (0) 
TB2 only 0 (0) 2 (11) 2 (9) 0 (0) 
TB1 or TB2 7 (88) 16(84) 20 (87) 3 (75) 
ICS 
CD4 
TB1 7 (88) 15 (79) 19 (83) 3 (75) 
TB2 7 (88) 17 (89) 21 (91) 3 (75) 
Concomitant TB1 and 
TB2 
7 (88) 15 (79) 19 (83) 3 (75) 
TB1 only 0 (0) 0 (0) 0 (0) 0 (0) 
TB2 only 0 (0) 2 (11) 2 (9) 0 (0) 
CD8 
TB1 2 (25) 2 (11) 3 (13) 1 (25) 
TB2 2 (25) 10 (53) 11 (48) 1 (25) 
Concomitant TB1 and 
TB2 
2 (25) 2 (11) 3 (13) 1 (25) 
TB1 only 0 (0) 0 (0) 0 (0) 0 (0) 
TB2 only 0 (0) 8 (42) 8 (35) 0 (0) 
Footnotes: Mtb: Mycobacterium tuberculosis; QFT: QuantiFERON; TB: tuberculosis; LTBI: latent tuberculosis 
infection; ICS: intracellular staining, N:number 
 
6.5 Discussion 
This is the first characterization of the CD4 and CD8 T-cell responses to TB1 and TB2 tubes of QFT-Plus assay 
in a cohort of subjects with active TB disease and LTBI enrolled in a low TB endemic country such as Italy. 
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We demonstrated that both, TB1 and TB2 induce a CD4 T-cell response. On the other hand, CD8 T-cell 
response is mainly due to TB2 stimulation which is largely associated to active TB. 
In an effort to find additional tools for performing better diagnosis using biomarkers (37), the QFT-Plus is a 
new generation IGRA designed to offer high sensitivity and specificity for LTBI diagnosis (29).  
In the absence of a gold standard for the diagnosis of LTBI, active TB patients are used as a surrogate to 
validate the test. In line with this, a recent study demonstrated that QFT-Plus, in comparison to QFT-GIT, 
improves the sensitivity for active TB detection maintaining a high specificity (23). Other two studies 
performed in low TB endemic country demonstrated that the performance of QFT-Plus is as accurate as 
that of QFT-GIT (27,28). Here we confirm that QFT-GIT and QFT-Plus have similar sensitivity for active TB 
diagnosis. Moreover in the LTBI population we confirmed by QFT-Plus the data generated by QFT-GIT. 
Several studies have described that CD8 T cells play a unique function in the recognition and containment 
of intracellular infection with Mtb, recognizing and eliminating heavily infected cells (38) including cells 
which do not belong to the immune system, such as the infected lung epithelial cells (39). Studies in the 
mouse model demonstrated that depletion of CD8 T cells in the chronic stage of Mtb infection results in 
increased bacterial burden (40). In vitro studies have shown that CD8 T cells may kill Mtb-infected human 
cells through granule-mediated functions such as granulysin (41). All these data together indicate that CD8 
T cells are actively involved in the immune response to Mtb and they are necessary for the control of TB 
infection. 
In the present study only few LTBI subjects showed a CD8 T-cell response. This is in accordance to the 
literature and to the concept that latent TB represents a spectrum of different stages in which the immune 
system and the mycobacteria find a host-pathogen equilibrium (42). In this environment, CD8 T cells are 
important players to control the Mtb bacterial load by emerging in the presence of replicating Mtb. This 
limits bacterial survival (41), but produces tissue damage. Interestingly, the decline of CD8 T-cell response 
in parallel with a decrease of Mtb replication has been described in active TB patients during TB treatment 
(12,21,43,44). In line with these results, we found lower CD8-specific responses in clinical TB compared to 
microbiologically diagnosed TB. This highlights that the monitoring of the CD8 T-cell response to TB2 by 
flow cytometry can be a tool to specifically evaluate treatment efficacy. Moreover we also show that TB2-
induced CD8 T-cell responses associate to the grade of TB severity.  
According to the manufacturer, TB1 peptides have been designed to stimulate CD4 T cells while TB2 should 
elicit both CD4 and CD8 responses. Unexpectedly, in the present study we showed that in a few subjects 
the CD8 response was detected also following TB1 stimulation. These subjects, equally spread between all 
evaluated groups, showed a concomitant TB2-dependent CD8 T cell-response. This is probably due to the 
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internalization and processing of the TB1 peptides by antigen presenting cells and their consequent 
presentation by the MHC I molecules to CD8 T cells. 
Recently, studies using QFT-Plus kit showed that the difference in IFN-γ production between TB2 and TB1 
stimulation may provide a surrogate marker of the CD8 T-cell response magnitude. This difference has been 
associated with smear positivity in active TB patients or with a recent exposure in TB contacts (23). In the 
present study, using the same approach, we did not find any association between these two parameters, 
probably due to the low number of recent LTBI subjects enrolled. 
In conclusion this is the first report on the characterization of the CD4 and CD8 T-cell response to TB1 and 
TB2 tubes of the QFT-Plus assay. We demonstrated that CD8 T-cell responses are preferentially induced by 
TB2 which are mainly associated to active TB. This assay has the potential to be very useful in conditions of 
immune depression resulting from CD4 T-cell impairments. 
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CHAPTER 7: ANALYTICAL EVALUATION OF QUANTIFERON- PLUS AND QUANTIFERON- GOLD IN-TUBE 
ASSAYS IN SUBJECTS WITH OR WITHOUT TUBERCULOSIS. 
 
 
7.1 Abstract 
The QuantiFERON-TB Gold Plus (QFT-Plus) represents the new QuantiFERON-TB Gold In-tube (QFT-GIT) to 
identify latent tuberculosis infection (LTBI). The main differences is the addition of a new tube containing 
shorter peptides stimulating CD8 T-cells. Aim of this study is to evaluate the accuracy of QFT-Plus compared 
with QFT-GIT in a cross sectional study of individuals with or without tuberculosis (TB). 
We enrolled 179 participants: 19 healthy donors, 58 LTBI, 33 cured TB and 69 active TB. QFT-Plus and QFT-
GIT were performed. 
The two tests showed a substantial agreement. Moreover we found a similar sensitivity in active TB and 
same specificity in healthy donors. A higher proportion of the LTBI subjects responded to both TB1 and TB2 
compared to those with active TB (97% vs 81%). Moreover, a selective response to TB2 was associated with 
active TB (9%) and with a severe TB disease, suggesting that TB2 stimulation induces a CD8 T-cell response 
in absence of a CD4-response. 
In conclusion, QFT-Plus and QFT-GIT assays showed a substantial agreement and similar accuracy for active 
TB detection. Interestingly, a higher proportion of the LTBI subjects responded concomitantly to TB1 and 
TB2 compared to those with active TB, whereas a selective TB2 response associated with active TB. 
 
7.2 Introduction 
Tuberculosis (TB), being responsible for 10.4 million cases and 1.4 million deaths annually, represents a 
major public health problem(1). Moreover, latent TB infection (LTBI), which is estimated to affect one-fifth 
of the world's population, may progress to active disease in about 3–15% of the LTBI individuals during 
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their lifetimes (2–4). Considering that LTBI subjects are the reservoir of TB disease, diagnosing and treating 
LTBI is one of the main goals to control and eliminate the TB epidemic (5–10). Tuberculin skin test (TST) and 
T-cell interferon-γ release assays (IGRAs) are the routine diagnostic tools to identify LTBI (6). Two IGRAs are 
commercially available: the QuantiFERON_-TB Gold In-Tube (QFT-GIT) (Qiagen, Hilden, Germany) and the T-
SPOT.TB (Oxford Immunotec, Abingdon, UK). IGRAs have several advantages: the results are not affected by 
Bacillus Calmette–Guérin (BCG)-vaccination (5–8) and by the majority of environmental mycobacteria; 
moreover, only one patient-visit is required. However, since these assays are based on detection of a 
Mycobacterium tuberculosis (Mtb) -specific immune response, they have a poor sensitivity in children 
where the immune system is immature and in immune-compromised subjects (8,11,12) furthermore IGRAs 
do not discriminate between active TB and LTBI (6) and poorly correlate with the presence of viable 
bacteria and the risk of developing active disease (4,13–15). 
Recently, QFT Gold Plus (QFT-Plus) (16–21), has been proposed as a new generation of QFT-GIT. QFT-Plus 
contains two TB-specific antigen tubes, called TB1 and TB2, for the incubation of the whole blood with Mtb 
antigens. The TB1 tube, contains long peptides derived from ESAT-6 and CFP-10 (TB-7.7, present in QFT-
GIT, has been removed), and it is designed to induce a specific CD4 T cells response. TB2 contains both the 
same long peptides of TB1 and newly designed shorter peptides to induce interferon (IFN)-γ production by 
both CD4 and CD8 T-cells (22). IGRA are designed to diagnose LTBI. However, there is not a gold standard 
for LTBI detection, therefore active TB is used as a surrogate reference standard for evaluating test 
accuracy (6). 
Compared to QFT-GIT, it has been reported that the accuracy of QFT-Plus is similar (18,23), or that the 
sensitivity for active TB or LTBI detection is higher (16,17). Moreover, in a low-incidence setting the 
occurrence of conversions and reversions for the new QFT-Plus in serial testing of a high-TB risk cohort (19) 
has been described similar to that observed for QFT-GIT (24). 
Therefore, the aim of this study is to evaluate the accuracy of the QFT-Plus assay compared with the QFT-
GIT in a cross sectional study of individuals enrolled as healthy donors, subjects with active TB disease, 
cured TB or LTBI. The response to QFT-Plus is selectively evaluated in terms of single or combined response 
to TB1 and TB2. 
7.3 Material and methods 
Population characteristics 
This study was approved by the Ethical Committee of “L. Spallanzani” National Institute of Infectious 
Diseases (INMI), approval number 72/2015. Written informed consent was required to participate in the 
study that was conducted at INMI. We prospectively enrolled HIV-uninfected patients with pulmonary and 
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extra-pulmonary active TB, cured TB subjects and LTBI. Enrolled patients were classified as “confirmed TB” 
if the diagnosis was based: i) in those with pulmonary TB by a positive culture for Mtb from the sputum or 
broncholavage; ii) in those with extrapulmonary TB by a) positive Mtb -specific RNA amplification 
(TRCReady M.TB, Tosoh, Japan) and/or Mtb -specific NAT (Home-made PCR (IS6110) GeneXpert, Cepheid; 
Genotype MTBDRPlus Hain Lifescience) from biological specimens or b) by histo-pathological findings 
consistent with TB and presence of acid fast bacilli (AFB) in a tissue sample or c) by positive culture for Mtb 
in clinical samples (pleural fluid and abscesses). Conversely, patients were classified as “clinical TB” if the 
diagnosis was based on clinical and radiologic criteria (having excluded other diseases) including 
appropriate response to standard anti-TB therapy. TB patients were enrolled within 7 days of starting the 
specific treatment. 
Cured TB patients were defined as those who had completed a 6-month course of treatment for culture-
positive (drug-susceptible) pulmonary TB and who resulted Mtb culture negative upon treatment 
completion. 
 
In the absence of clinical, microbiological and radiological signs of active TB, LTBI was defined based on a 
positive score to QFT-GIT (Qiagen, Hilden, Germany). Finally, we enrolled 19 healthy control subjects with 
low risk of TB infection. Demographic and epidemiological information were collected at enrollment (Table 
1). 
Chest X-ray evaluation 
All chest X-rays were evaluated blind to operators for the presence of nodules, fibrosis, infiltrates, 
cavitation, bronchial spread, miliarity, pleural effusion and adenopathy, as previously reported(25). Cavity 
size in centimeters was recorded (<4 cm or >4 cm). The proportion of the affected lung was analyzed by a 
visual estimate of the extent of parenchymal infiltrates; a proportion of 30% of affected lung was used as 
our internal cut-off value to grade TB severity. In agreement with literature data(25) and on the basis of 
experience, the disease was graded (by DG, FP) using a sliding scale of severity as follows: 0: normal chest 
X-rays; 1: mild grade (nodules and or infiltrates with proportion of lung affected <30%); 2: intermediate 
grade (infiltrates with proportion of lung affected >30% and/or cavitation <4 cm in diameter); 3: high grade 
(an infiltrate of any percentage of extension with cavitation >4 cm in diameter and/or bronchial spread 
and/or miliarity and/or pleural effusion and/or adenopathy). All subjects underwent standard chest X-rays 
at the time of TB diagnosis. 
QFT-GIT and QFT-Plus 
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QFT-GIT and QFT-Plus assays were performed for each subject enrolled. For 11 patients the QFT-GIT value 
of IFN-γ production was not available because the assay was done in another hospital and only the score of 
the test was provided. QFT-Plus kits were donated by Qiagen and used according to manufacturer's 
instructions(22). Levels of IFN-γ were quantified by ELISA. The results were analyzed by a QFT-Plus Analysis 
Software (available from www.quantiFERON.com). The software performs a quality control assessment of 
the assay, generates a standard curve and provides a test result for each subject. Test results were analyzed 
according to manufacturer's criteria for both assays(22). All patients resulted positive to mitogen 
stimulation. 
Statistical analysis 
Data were analyzed using SPSS software (Version 19 FORWindows, Italy SRL, Bologna, Italy). The median 
and interquartile ranges (IQRs) were calculated for continuous measures. Chi square was used for 
categorical variables. The Kruskall Wallis test was used for comparisons among several groups and the 
Mann Whitney U test was used for pairwise comparisons. Test concordance was assessed by k-statistics 
where k ≤ 0.20 was considered ‘slight’, 0.20 < k ≤ 0.40 ‘fair’, 0.40 < k ≤ 0.60 ‘moderate’, 0.60 < k ≤ 0.80 
‘substantial’ and 0.80 < k ≤ 1.00 ‘optimal’. 
7.4 Results 
Population characteristics 
We enrolled 179 participants: 19 healthy donors, 58 LTBI subjects, 33 cured TB and 69 active TB patients. 
Among the active TB patients, 49 were microbiologically confirmed (among them two patients had an 
extra-pulmonary form) and 20 clinically diagnosed (4 patients had an extra-pulmonary form). Forty-seven 
percent of the enrolled subjects were from Western Europe and female. The majority of TB and cured TB 
patients were from countries other than west Europe and they were BCG-vaccinated, consequently we 
found significant differences for BCG vaccination and origin among the different groups (Table 1). 
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Table 1: Demographic characteristic of enrolled patients  
 
Active 
TB  
LTBI Cured TB  Healthy donors  Total  p  
N  (%)  69 (38)  58 (32)  33 (18)  19 (10.5)  179  
 
Sex  
female N (%)  
28(41)  30 (52)  15(45)  10(53)  84(47)  0.6 
§ 
 
Age 
median (IQR)  
35 (28-
44)  
42(31.75-57)  35 (28.5-42.5)  43 (33-48)  
38 ( 29-
47)  
0.02
 # 
 
BCG-vaccinated 
N(%)  
49 (71)  *23 (40)  24 (73)  1 (5)  98 (54)  ≤0.0001
 #
  
Origin (%) 
     
≤0.0001
 #
  
West Europe  20 (29)  36 (62)  9 (27)  19(100)  84 (47)  
 
East Europe  26 (38)  17 (29)  13  (39)  0 (0)  55 (30.5)  
 
Asian  11 (16)  1 (2)  5(15)  0 (0)  19 (10.5)  
 
Africa 7 (10)  3 (5)  4(12)  0 (0)  14 (8)  
 
South America 5 (7)  1 (2)  2(6)  0 (0)  7 (4)  
 
Central America  0 (0)  0 (0)  0 (0)  0 (0)  1 (0.5)  
 
Footnotes: TB: tuberculosis; LTBI: latent tuberculosis infection; BCG: Bacillus Calmette et Guérin;
  
§
Kruskal Wallis test ; 
#
Chi Square test ; *For one patient  the BCG-vaccination status is not available  
 
Concordance between QFT-GIT and QFT-Plus assays 
First, we evaluated the accuracy of the QFT-Plus and QFT-GIT assays. The sensitivity of QFT-Plus in active TB 
cases, based on the response to either TB1 or TB2 (“either TB1 or TB2”), was 90% (62/69) (Table 2), the 
specificity calculated on the low TB risk population of healthy donors was 100% (19/19); similarly the 
sensitivity of the QFT-GIT assay was 88% whereas the specificity 100% (Table 2). The proportion of 
response to QFT-Plus were significantly different comparing TB vs LTBI group (p = 0.007) and LTBI vs cured 
TB (p = 0.02) (Table 3). 
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 Agreement between QFT-Plus and QFT-GIT results was evaluated (Table 2). The concordance among all 
samples evaluated was substantial (k = 0.8). In active TB, a moderate agreement (k = 0.5) was achieved 
whereas for cured TB it was substantial (k = 0.7). In the LTBI group one patient scored positive by QFT-GIT 
resulted negative by QFT-Plus; it was not possible to evaluate the agreement because the QFT-GIT score 
was a constant. 
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Analysis of the QFT-Plus results based on the response to TB1 and TB2 tubes 
To analytically evaluate the response to the peptides contained in TB1 and TB2 tubes, we stratified the 
QFT-Plus results according to the ability of subjects to respond to both TB1 and TB2 (“TB1 and TB2”), only 
to TB1 (“only TB1”) or only to TB2 (“only TB2”). We found that almost all LTBI subjects (97%) responded to 
both “TB1 and TB2” while among TB patients and cured TB only 81% and 82% respectively responded. 
These proportions were significantly different comparing TB vs LTBI group (p = 0.007) and LTBI vs cured TB 
(p = 0.02) (Table 3). 
Interestingly, a selective response to TB2 was found only among those with active TB (6/69, 9%). 
Regarding the stimulation to TB1, the responders were: 81% within TB patients, 98% within LTBI and 82% 
within cure TB. These proportions were significantly different comparing TB vs LTBI group (p = 0.002) and 
LTBI vs cured TB (p = 0.005) (Table 3). 
Regarding the cumulative response to TB2, the responders were: 90% within the TB patients, 97% in LTBI 
and 82% in the cured TB. These proportions were significantly different comparing LTBI vs cured TB group 
(p = 0.02) (Table 3). 
Interestingly, in the active TB group a higher proportion of patients responded to TB2 compared to TB1 
(90% vs 81%). The higher sensitivity of the TB2 stimulation was likely due to the CD8-specific peptides 
contained in the TB2 tube and consequently to the presence of Mtb-specific CD8 T-cells(26). 
 
 
Impact of mycobacterial load and severity of TB disease on the QFT-Plus assay results 
To evaluate the impact of the mycobacterial load on the immunological response to QFT-Plus, we stratified 
the active TB patients according to the microbiological diagnosis. Interestingly we found that the six 
patients showing an “only TB2” response had a microbiological diagnosis (Table 4). 
Moreover, we investigated whether the severity of pulmonary TB disease had an impact on the response to 
QFT-Plus. Clinical severity was estimated evaluating the lung lesions based on the radiological findings. The 
radiological data from 63 pulmonary TB patients were analyzed: patients characterized by an 
intermediate/high radiological severity (grades 2 and 3) were combined and compared with those from 
patients with low radiological severity (grade 1). As shown in Table 5 the patients with intermediate/high 
radiological severity TB had a similar proportion of responders (91%) to either TB1 or TB2 compared to the 
patients with low radiological severity (88%). Interestingly, we found that the six TB patients showing “only 
TB2” response (Table 3) were classified as: 5 with high/intermediate radiological severity and only 1 with 
low radiological severity (Table 5). 
These results suggest that CD8 T-cell response associates with the radiological severity of TB disease (Table 
5) and with the mycobacterial load (Table 4). 
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Comparison of IFN-γ production using QFT-Plus and QFT-GIT 
We evaluated the results also by quantitative means (Fig. 1). Using the QFT-Plus, we found that in the TB 
group the median of TB1 response (1.9 IU/mL, IQR: 0.7–6.8) was significantly lower than that observed in 
LTBI (5.6 IU/mL, IQR: 2–10) (p = 0.0007). Similar results were obtained in response to TB2, the median in 
active TB (2.5 IU/mL, IQR: 0.9–7.5) was significantly lower than in LTBI (7.3 IU/mL, IQR: 1.9–10) (p = 0.003). 
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The cured TB group showed levels of IFN-γ production similar to that reported in the active TB (TB1: 1.9 
UI/ml, IQR: 0.6–8.2 and TB2: 2.3 UI/ml, IQR: 0.5–8.2). Comparing the cured TB group with LTBI we found 
significant differences in response to TB1 (p = 0.016). These results suggest that LTBI subjects have a higher 
immunological ability to respond to Mtb stimulation compared to those that experienced a higher Mtb 
load. Regarding the QFT-IT, we found that the median production of IFN-γ in response to AgTB stimulation 
was higher, although not significant, in the LTBI (5.6 UI/mL, IQR: 2–10) than in active TB (2.6 UI/mL, IQR: 1–
8) and significantly higher compared to cured TB subjects (1.6 UI/mL, IQR: 0.2–7) (p = 0.01). 
 
Figure. 1. Quantitative IFN-γ response to stimulation with QFT-Plus antigen TB1 and TB2 and QFT-GIT antigen AgTB. 
Horizontal lines indicate the median production. A p ≤ 0.016 was considered significant after Bonferroni correction. 
The data are presented as IU/ml. Footnotes: IFN: interferon; IU: international unit. 
7.5 Discussion 
We evaluated in a low TB endemic country such as Italy, the accuracy of QFT-Plus in comparison to QFT-
GIT, dissecting the response to TB1, TB2 and AgTB in a cohort of subjects with LTBI, active TB, cured TB and 
healthy donors. The accuracy for active TB detection of QFT-Plus was similar to that found for QFT-GIT. The 
two tests showed a substantial agreement and similar sensitivity in active TB patients and same specificity 
in the healthy donors. Interestingly, the majority of the LTBI subjects responded concomitantly to both 
QFT-Plus antigens TB1 and TB2 compared to the active TB (97% vs 81%); moreover, the response “only to 
TB2” was associated to active TB. 
Based on the product information (22), TB1 contains long peptides eliciting a CD4 T-cell response whereas 
TB2, beside the same long peptides, contains additional short peptides specific for the CD8 T-cells. 
Therefore, when a selective response to TB2 is found, it is plausible to assume that the CD8 T-cells played a 
role in this antigen recognition otherwise, the response should have been observed also in response to TB1. 
Differently, if a simultaneously response to “either TB1 or TB2”, is found, the reasonable scenario is that 
CD4 T-cells recognize the CD4 peptides present in TB1 and TB2 tubes. Therefore stratifying the QFT-Plus 
results according to the ability of subjects to respond or not simultaneously to TB1 and TB2, we found that 
among the LTBI subjects the majority of them responded to both TB1 and TB2 stimulation (97%). Based on 
the assay format, it is unknown whether the response to TB2 is mediated by the CD8 or CD4 T-cells. 
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Conversely, among the active TB patients showing “only TB2” response, it can reasonably be assumed that 
this response is mediated by CD8 T-cells. By cytometry this result could have been more refined, as we 
recently showed that the CD8 T-cells are mainly induced by TB2 and are associated to active TB (in 44%) 
although it may be found at a lower proportion also in LTBI (in 11%) (26). 
Several studies have described that CD8 T cells play a unique function in the recognition and containment 
of intracellular infection with Mtb. CD8 T cells are important players to control the Mtb bacterial load, 
emerging in the presence of replicating Mtb and declining during TB treatment (15). Interestingly, in our 
study we did not observe any “only TB2” response after the completion of TB therapy, suggesting a loss of 
the CD8 T-cell response in parallel with the decrease of mycobacterial load. Therefore, investigation of the 
TB1 and TB2 response could be a springboard to find new tools to monitor the efficacy of TB therapy. 
In line with the literature reporting a correlation between mycobacterial load and CD8 T-cell response (15), 
we found that patients showing a selective “only TB2” response had a microbiologically diagnosed TB. 
Interestingly, we showed that the majority of them had an intermediate/high level of TB severity, 
supporting the concept that CD8 T-cells limit bacterial survival and at the same time produce tissue 
damage(27). These data confirm recent findings generated by cytometry(26). Altogether, these results 
suggest that the Mtb load and consequently the lung damage may influence the ability to respond to the 
peptides specific for the CD8 T-cells, contained in the TB2 tube. 
In those with active TB and cured TB a proportion of patients was scored as negative to QFT-GIT and QFT-
Plus. This can be due in those with active TB group to a higher amount of specific cells at site of TB disease 
compared to peripheral blood (28,29); differently, in the cured TB to a decrease of Mtb load after therapy. 
Looking at the quantitative levels of the IFN-γ produced, the LTBI subjects showed higher IFNγ levels in 
response to either TB1, or TB2 stimulation compared to the active TB patients. These results are mainly due 
to the absence of IFN-γ production in 7 patients with active TB. 
We found that within the group of patients evaluated, the stimulation with either TB1, or TB2 or AgTB 
induced similar level of IFN-γ. Therefore, the absence of TB7 peptides in the QFT-Plus did not reduce the 
IFN-γ response. This finding is different from what recently reported in two studies performed in Japan and 
Germany in which it was described that the QFT-GIT induced higher level of IFN-γ compared to QFT-Plus in 
active TB patients (18,23) and the QFT-Plus induced higher IFN-γ amount in LTBI subjects (23). Regarding 
the German study, the data of QFT-Plus and QFT-GIT are related to the total cohort of patients with LTBI 
and TB, making difficult the comparison with our findings (18). 
Using the QFT-Plus, we indirectly demonstrated that TB2 stimulation induces a CD8 T-cell response in 
absence of a CD4 T-cell response in the active TB patients. This ability to selectively induce a TB2 response 
could be potentially very useful in conditions of immune depression resulting from CD4 T-cell impairments. 
In line with this, it has been recently published a study demonstrating that human immunodeficiency virus 
(HIV) infection did not reduce the sensitivity of the QFT-Plus for active TB detection (30). Moreover, the 
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comparison of QFT-Plus and QFT-IT results in co-infected HIV-TB subjects, demonstrated the higher 
sensitivity of the QFT-Plus compare to QFT-IT (30,31). 
Future studies on patients with different stages of Mtb infection, followed overtime during TB treatment 
could be useful to characterize distinct profile of Mtb-specific response to distinguish LTBI and active TB 
patients and to monitor TB therapy efficacy as previously suggested with different experimental settings 
(32–35) and as recently proposed with QFT-Plus assay (36). 
In conclusion, this is the first report of the characterization of TB1, TB2 and AgTB response of the QFT-Plus 
and QFT-GIT assays respectively done in healthy donors and subjects with active TB disease, cured TB and 
LTBI. We demonstrated that the two tests have similar accuracy. Moreover, we indirectly demonstrated 
that TB2 stimulation induces a CD8 T-cell response in absence of a CD4 T-cell response in the active TB 
patients. 
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CHAPTER 8:  GENERAL DISCUSSION  
New approaches to control tuberculosis worldwide are needed. In particular, new tools for diagnosis and 
new biomarkers are required to evaluate pathogen stage of infection and host response. Non-sputum 
based diagnostic tests, biomarkers predictive of adequate responsiveness to treatment, and biomarkers of 
risk of developing active TB disease are major goals. These tests need to perform in endemic settings with 
limited laboratory facilities, at low cost, using easily accessible non-sputum based samples such as blood, 
urine, or breath. These are the four high priority target product profiles (TPPs) recently published by the 
WHO as a result of a consensus meeting on new TB diagnostics (71). Therefore the urgent need to search 
for biomarkers (defined as measurable characteristics that indicate normal or pathogenic biological 
processes, or pharmacological responses to therapeutic intervention) (72) needs to be highlighted: 
biomarkers can serve as surrogate endpoints in clinical trials, and can be used to improve treatment 
outcome by informing therapeutic decisions for individual patients (73). By contrast, a diagnostic test 
classifies patients at a single time point as having active tuberculosis, latent infection with Mtb, or neither. 
Biomarkers can be either host or pathogen specific and tuberculosis-specific ones are needed to serve as 
surrogate endpoints, assisting candidate selection during drug discovery, accelerating dose selection in 
early clinical studies, shortening the time to licensing of new drugs, and development and assessment of 
new vaccines for tuberculosis (13). 
 
Mtb is able to establish a chronic asymptomatically infection mainly in the lung and the balance between 
host immune response and the mycobacteria plays a fundamental role in the control of the Mtb replication 
(31,36). Although the immune response to Mtb has been deeply studied, as described in the previously 
chapters, the host factors that lead to the development of active TB disease are not fully understood. 
However, on the base of immunological findings on Mtb infection, it is possible to speculate that the 
containment of the latent Mtb needs an acquired cellular response with specific characteristics of immune 
surveillance, differently, contrasting the replicating Mtb requires effector and cytotoxic proprierty. 
Moving from these hypothesis the studies reported in this manuscript have demonstrated the following 
findings: 
 The loss of the CD27 significantly associates with active TB patients. This modulation has been 
described also in other studies with different experimental settings and in different countries 
(74,75). Therefore, this activation marker of Mtb specific T- cells has the required characteristics to 
be exploit as a TB biomarker for routine use.  
 The QFT-Plus has a new tube containing peptides to stimulates both CD4 and CD8 T-cell response. 
Using a cytometer approach, we found that TB2 stimulation induced the CD8 T-cell response 
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preferentially in active TB patients. This assay has the potential to be very useful in conditions of 
immune depression resulting from CD4 T-cell impairments. Moreover, we found lower CD8-specific 
response in clinical TB compared to microbiologically diagnosed TB. This result suggests that the 
monitoring of the CD8 T-cell response to TB2 by flow cytometry can be a tool to specifically 
evaluate treatment efficacy.  
 The comparison between QFT-Plus performance and that one of QFT-GIT has shown similar 
accuracy. Moreover, TB2 stimulation induces a CD8 T-cell response in absence of a CD4 T-cell 
response in the active TB patients as demonstrated by the presence of responders only to TB2 
stimulation. In line with the literature reporting a correlation between mycobacterial load and CD8 
T-cell response (76), we found that patients showing a selective “only TB2” response had a 
microbiologically diagnosed TB. Interestingly, we showed also that the majority of them had an 
intermediate/high level of TB severity, supporting the concept that CD8 T-cells limit bacterial 
survival and at the same time produce tissue damage (77). These data suggest that the TB2 
response could be used to monitor the therapy and therefore the lung damage.    
Even though the immunological studies have the limit to be useful only in the IGRA positive individuals, 
they could quickly describe an immunological profile possibly associated to TB and they could be used in 
patients usually tested negative to traditional sputum test (such as HIV positive subjects and children). As 
demonstrated by the study of Portevin, the CD27 modulation is able to diagnose TB in children in a high TB 
endemic country such as Tanzania (75). Moreover, monitoring CD27 expression has been used also to 
evaluate Mtb activity in HIV-1 infected individuals in vivo (78). 
The available tools to monitor the efficacy of the TB therapy are the Mtb culture and the xRay evaluation, 
whereas there are not known correlates of protection to evaluate the efficacy of prophylaxis in LTBI 
subjects. Effective therapy is central to any strategy for controlling TB and biomarkers that indicate 
initiation of successful treatment could facilitate development of alternative treatment strategies. 
Considering the lack of correlates of protection, quick and easy to evaluate, to track the TB evolution, 
longitudinal study in patients followed overtime could be useful to characterize distinct immunological 
profile to monitor TB therapy and prophylaxis. 
 
Although studies on new candidate biomarkers are numerous, validation and independent confirmation are 
rare. Efforts are needed to reduce the gap between the exploratory up-stream identification of candidate 
biomarkers, the validation of biomarkers against clear clinical endpoints in different populations, and the 
development of simple point of care tests for use in low resourced settings. This needs important 
commitment from both researchers and economic funders (15). 
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It is becoming clear that biomarkers, and the associations they generate, are probably specific and 
restricted to the population under study and might not necessarily be broadly applicable (3). Therefore, 
natural implication of biomarkers studies is the needed to validate the test in a larger population and in 
different geographical settings. In fact, patients from high TB endemic country could be exposed many 
times to Mtb, reflecting a different immune response to a repeated antigen stimulation. Moreover, 
different host genetic backgrounds and circulating pathogen lineages could influence the accuracy of the 
test (3). 
To compare data from immunological test performed in different laboratory it is necessary to uniform the 
experimental settings. The choice of type of antigen (protein or peptide),  the time of stimulation, the T- 
cell source (PBMC versus whole blood), the use of daily quality control to check the cytometer performance 
are all factors to be considered. Customized antibody specifically produced for the study could be useful to 
eliminate the bias due to the use of different fluorochrome to detect the antigen specific T cells. 
The QFT-Plus is routinely used for the diagnosis of latent infection, the addition of peptides to elicit the CD8 
response gives the possibility to deeply study the immune response to Mtb with a standardize IGRA. The 
QFT-Plus has been developed to improve the sensitivity of the QFT-IT stimulating also the CD8 T-cells, 
therefore the TB2 contains peptides able to induce IFN-γ production from both CD4 and CD8 T- cells. This 
characteristic of the test is an intrinsic limit for research purpose studying only the CD8 response, however 
it puts the accent on the needed of new antigen formulation to dissect the Mtb immune response. 
Moreover, the data obtained in PBMC stimulated with TB2 highlight the importance of CD8 T-cell subset 
during  the Mtb infection, showing an association with the active TB disease that should be deeply studied 
in future studies evaluating also the T cell phenotype with activation and memory markers.     
   
The study of biomarkers of TB is a topic of translational research of great interest for the scientific 
community. The NIH gives the following definition of translational research:  
Translational research includes two areas of translation. One is the process of applying discoveries 
generated during research in the laboratory, and in preclinical studies, to the development of trials and 
studies in humans. The second area of translation concerns research aimed at enhancing the adoption of 
best practices in the community. Cost-effectiveness of prevention and treatment strategies is also an 
important part of translational science  (79). 
According to this definition, translational research is part of a unidirectional continuum in which research 
findings are moved from the researcher’s bench to the patient’s bedside and community. In the continuum, 
the first stage of translational research (T1) transfers knowledge from basic research to clinical research, 
while the second stage (T2) transfers findings from clinical studies or clinical trials to practice settings and 
communities, where the findings improve health (79). 
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The study of immunological profile of Mtb infected subjects belongs to the first stage of translational 
research. A recent example of the application of translational research to a routine test is the development 
of the QFT-Plus and QFT-IT. In fact, the studies on the CD8 response (76,80) have suggested to stimulate 
the CD8 response to improve the accuracy of the QFT-IT and studies on Mtb specific response have inspired 
the development of the IGRA (49). 
 
In conclusions, further intensified research efforts are required for ongoing biomarker discovery, evaluation 
and test development and translation of the test to a near-patient platform.   
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